View Filing Data

Print Document View Excel Document

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2017
Document And Entity Information [Abstract]
Document Type	S-1/A
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Trading Symbol	DCTH
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2017

Dec. 31, 2016

Dec. 31, 2015

Current assets

Cash and cash equivalents

$ 2,495

$ 4,409

$ 12,607

Restricted cash

8,362

27,287

Accounts receivables, net

298

403

277

Inventories

1,164

660

757

Prepaid expenses and other current assets

385

698

960

Deferred financing costs

529

699

Total current assets

13,233

34,156

14,601

Property, plant and equipment, net

1,253

1,083

1,132

Total assets

14,486

35,239

15,733

Current liabilities

Accounts payable

1,891

594

284

Accrued expenses

3,755

3,407

2,243

Series C preferred shares

494

Convertible notes payable, net of debt discount

9,736

13,343

Warrant liability

18,751

3,785

Total current liabilities

15,892

36,095

6,312

Deferred revenue

Other non-current liabilities

444

604

820

Total liabilities

16,336

36,729

7,132

Commitments and Contingencies

Stockholders' Equity (Deficit)

Preferred stock

Common stock

^[1]

Additional paid-in capital

303,808

277,790

269,863

Accumulated deficit

(305,587)

(279,188)

(261,217)

Treasury stock

^[1]

(51)

Accumulated other comprehensive income

(34)

(41)

(8)

Total stockholders' deficit

(1,850)

(1,490)

8,601

Total liabilities and stockholders' deficit

$ 14,486

35,239

$ 15,733

Scenario, Previously Reported [Member]

Stockholders' Equity (Deficit)

Common stock

Additional paid-in capital

$ 277,749

[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0	0
Preferred stock, shares outstanding (in shares)	0	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000	500,000,000
Common stock, shares issued (in shares)	1,426,153	11,805	1,396,344
Common stock, shares outstanding (in shares)	1,425,862	11,750	1,360,239
Treasury stock, at cost (in share)	1	1	110
Scenario, Previously Reported [Member]
Common stock, shares issued (in shares)		4,131,527
Common stock, shares outstanding (in shares)		4,112,417
Treasury stock, at cost (in share)		110

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Income Statement [Abstract]

Revenue

$ 684

$ 435

$ 2,011

$ 1,316

$ 1,992

$ 1,747

Cost of goods sold

172

112

527

373

550

462

Gross profit

512

323

1,484

943

1,442

1,285

Operating expenses:

Selling, general and administrative

2,860

2,361

7,807

7,025

9,434

10,009

Research and development

2,279

2,686

7,119

5,975

8,448

6,486

Total operating expenses

5,139

5,047

14,926

13,000

17,882

16,495

Operating loss

(4,627)

(4,724)

(13,442)

(12,057)

(16,440)

(15,210)

Change in fair value of the warrant liability, net

8,680

1,227

9,171

12,780

564

Derivative instrument income

12,780

564

Gain on warrant extinguishment

9,613

Interest income

Loss on debt settlements

(2,952)

Interest expense

(5,042)

(4,963)

(20,324)

(6,584)

Other income (expense)

(2)

(15)

(14,328)

(67)

Net loss

(12,596)

(1,004)

(25,873)

(9,485)

(17,971)

(14,704)

Other comprehensive loss:

Foreign currency translation adjustments

(15)

(2)

(12)

(33)

(28)

Comprehensive loss

$ (12,611)

$ (1,006)

$ (25,866)

$ (9,497)

$ (18,004)

$ (14,732)

Common share data:

Basic and diluted loss per share

^[1]

$ (9.36)

$ (230.99)

$ (34.99)

$ (2,232.30)

$ (10.59)

$ (14.56)

Weighted average number of basic and diluted common shares outstanding

^[1]

1,401,413

4,349

754,421

4,249

1,696,237

1,010,105

[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016
Reverse stock split ratio		0.0625
Subsequent Event [Member]
Reverse stock split ratio	0.0029

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive loss [Member]
Balance at Dec. 31, 2014	$ 18,145	$ 6	$ (51)	$ 246,513	$ (246,513)	$ 20
Balance (in shares) at Dec. 31, 2014		608,775	(110)	64,683
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	349			$ 349
Compensation expense for issuance of restricted stock	308			308
Compensation expense for issuance of restricted stock (in shares)		35,991
Sale of common stock, net of expenses	8,479	$ 8		8,471
Sale of common stock, net of expenses (in shares)		738,125
Warrants exercised	176			176
Warrants Exercised (in shares)		13,457
Fair value of warrants issued classified as liability	(4,247)			(4,247)
Fair value of warrants exercised	123			123
Net loss	(14,704)				(14,704)
Total comprehensive loss	(28)					(28)
Balance at Dec. 31, 2015	8,601	$ 14	$ (51)	269,863	(261,217)	(8)
Balance (in shares) at Dec. 31, 2015		1,396,348	(110)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	161			161
Compensation expense for issuance of restricted stock	266			266
Compensation expense for issuance of restricted stock (in shares)		2,180
Sale of common stock, net of expenses	1,011	$ 4		1,007
Sale of common stock, net of expenses (in shares)		428,067
Issuance of common stock for payments made in shares on convertible note payable	649	$ 18		631
Issuance of common stock for payments made in shares on convertible note payable (in shares)		1,805,299
Fair value of Beneficial conversion feature of convertible note	4,435			4,435
Warrants exercised	1,372	$ 5		1,367
Warrants Exercised (in shares)		499,633
Fair value of warrants issued classified as liability	(707)			(707)
Fair value of warrants exercised	726			726
Net loss	(17,971)				(17,971)
Total comprehensive loss	(33)					(33)
Balance (Scenario, Previously Reported [Member]) at Dec. 31, 2016		$ 41		277,749
Balance at Dec. 31, 2016	(1,490)		$ (51)	277,790	(279,188)	(41)
Balance (in shares) (Scenario, Previously Reported [Member]) at Dec. 31, 2016		4,131,527	(110)
Balance (in shares) at Dec. 31, 2016		11,805	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	48			48
Compensation expense for issuance of restricted stock	84			84
Compensation expense for issuance of restricted stock (in shares)		261
Issuance of common stock for payments made in shares on convertible note payable	25,866	$ 14		25,852
Issuance of common stock for payments made in shares on convertible note payable (in shares)		1,413,790
Series B preferred stock dividend	(526)				(526)
Warrants exercised	15			15
Warrants Exercised (in shares)		297
Fair value of warrants exercised	19			19
Net loss	(25,873)				(25,873)
Total comprehensive loss	7					7
Balance at Sep. 30, 2017	$ (1,850)	$ 14	$ (51)	$ 303,808	$ (305,587)	$ (34)
Balance (in shares) at Sep. 30, 2017		1,426,153	(1)

Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016 $ / shares	Sep. 30, 2017 $ / shares	Dec. 31, 2016 $ / shares	Dec. 31, 2015 $ / shares
Reverse stock split ratio		0.0625
Common stock issued, par value		$ 0.01	$ 0.01	$ 0.01	$ 0.01
Subsequent Event [Member]
Reverse stock split ratio	0.0029

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (25,873,000)	$ (9,485,000)	$ (17,971,000)	$ (14,704,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	48,000	138,000	161,000	349,000
Restricted stock compensation expense	84,000	228,000	266,000	308,000
Depreciation expense	198,000	232,000	305,000	617,000
Loss on disposal of equipment	20,000	1,000	1,000	15,000
Warrant liability fair value adjustment	(1,227,000)	(9,171,000)	(12,780,000)	(564,000)
Gain on warrant extinguishment	(9,613,000)	0
Non-cash interest income	16,000	(1,000)	(1,000)	(1,000)
Deferred revenue	(30,000)	31,000
Debt discount and deferred finance costs amortization	20,315,000	6,567,000	14,268,000
Loss on debt settlements	2,952,000	0
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	276,000	610,000	260,000	9,000
Increase in accounts receivable	(94,000)	(94,000)	(138,000)	(52,000)
Decrease (increase) in inventories	(338,000)	190,000	95,000	(420,000)
Increase (decrease) in accounts payable and accrued expenses	1,767,000	312,000	1,507,000	(1,757,000)
Increase in deferred revenue			30,000
Decrease in other non-current liabilities	(160,000)	(155,000)	(216,000)	(220,000)
Net cash used in operating activities	(11,659,000)	(10,597,000)	(14,213,000)	(16,420,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(372,000)	(245,000)	(258,000)	(170,000)
Increase in restricted cash	0	(1,087,000)	(1,087,000)
Proceeds from sales of property, plant and equipment				180,000
Net cash provided by (used in) investing activities	(372,000)	(1,332,000)	(1,345,000)	10,000
Cash flows from financing activities:
Increase in restricted cash	0	(29,200,000)	(26,200,000)
Net proceeds from the release of restricted cash	7,901,000	0
Net proceeds from sale of Series B and Series C preferred shares	2,278,000	0
Net proceeds from convertible debt financing	0	31,436,000	31,226,000
Net proceeds from sale of stock and exercise of warrants	15,000	704,000	2,383,000	8,655,000
Net cash provided by financing activities	10,194,000	2,940,000	7,409,000	8,655,000
Foreign currency effects on cash and cash equivalents	(77,000)	71,000	(49,000)	(107,000)
Net decrease in cash and cash equivalents	(1,914,000)	(8,918,000)	(8,198,000)	(7,862,000)
Cash and cash equivalents:
Beginning of period	4,409,000	12,607,000	12,607,000	20,469,000
End of period	2,495,000	3,689,000	4,409,000	12,607,000
Supplemental non-cash activities:
Conversion of convertible notes	26,199,000	0	649,000
Fair value of warrants issued	0	28,133,000	28,472,000	4,247,000
Fair value of warrants exercised	19,000	245,000	$ 726,000	$ 123,000
Series A and Series B Preferred Shares [Member]
Cash flows from financing activities:
Release of restricted cash for redemption of Series A and Series B preferred shares	2,360,000	0
Redemption of Series A and Series B preferred shares	(2,360,000)	0
Series C Warrants [Member]
Cash flows from financing activities:
Release of restricted cash for extinguishment of Series C Warrants	7,876,000	0
Cash paid to extinguish of Series C Warrants	$ (7,876,000)	$ 0

Description of Business

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

(1)

Description of Business

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is in commercial development under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (CHEMOSAT^®), where it has been used at major medical centers to treat a wide range of cancers of the liver.

Our primary research focus is on ocular melanoma liver metastases (mOM), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need.

Liquidity

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has accumulated deficit of $279.2 million at December 31, 2016. As shown in the accompanying financial statements during the year ended December 31, 2016, the Company incurred net losses of $18.0 million and used $14.2 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If we are not able to continue as a going concern, it is likely that holders of our common stock will lose all of their investment. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. On June 13, 2016 we issued an aggregate $35 million principal amount of senior secured convertible notes (the “Notes”). As a result, Management believes that its capital resources are adequate to fund operations through the first quarter of 2018, but anticipates that additional working capital will be required to continue operations. The Notes are payable in fourteen equal installments beginning in January 2017. Although the Notes are payable through the issuance of shares of our common stock to the noteholders, our ability to issue stock, instead of paying cash, to satisfy our payment obligations under the Notes, is limited and subject to various conditions (including trading volume and stock price conditions for these Notes) that we may not be able to meet. If we cannot meet these conditions, we could be required to repay some or all of the amounts due under the Notes in cash, and we may not have the funds available to make one or more of such payments when due. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing or sales experience; and dependence on key personnel.

Basis of Consolidated Financial Statement Presentation

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Consolidated Financial Statement Presentation

(2)

Basis of Consolidated Financial Statement Presentation

The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company’s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

(3)

Summary of Significant Accounting Policies

Use of Estimates

The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.

Cash Equivalents and Concentrations of Credit Risk

The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.

Restricted Cash

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying consolidated balance sheets. On June 13, 2016, the Company issued $35.0 million in senior secured convertible notes and received $32.2 million in cash proceeds. Under the terms of the notes, at closing, an initial tranche of $3.0 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $29.2 million were available in a tranche of $3.0 million on December 29, 2016 (“First Release Date”) and the remainder of $26.2 million will be available in four equal tranches to be released quarterly, beginning in February 2017 (“Subsequent Release Dates”), pursuant to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions. The terms of the Notes are discussed in more detail in Note 9 contained in this Annual Report on Form 10-K. The cash is deposited in an account that is not FDIC insured.

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified.

Inventories

Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory.

Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2016 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2016 and 2015, the Company did not have any derivative instruments that were designated as hedges.

Fair Value Measurements

The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

•

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

•

Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.

•

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Revenue Recognition

Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.

Deferred Revenue

Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied.

Selling, General and Administrative

Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred.

Research and Development

Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.

Stock Based Compensation

The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant.

The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

Income Taxes

The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. See Note 13 for additional information.

Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2016 and 2015 are as follows:


(in thousands, except share data)	2016			2015
Net loss – basic and diluted	$	(17,971	)	$	(14,704	)
Net loss per share – basic and diluted		(10.59	)		(14.56	)
Weighted average shares outstanding – basic and diluted		1,696,237			1,010,105

For the years ended December 31, 2016 and 2015, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive.

Shares excluded from the computation of diluted EPS:


	2016		2015
Stock options		41,356		47,221
Unvested restricted shares		18,993		35,955
Warrants		7,216,020		1,128,688

Total		7,276,369		1,211,864

All share numbers presented in this footnote reflect a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016.

Segment Information

The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Foreign Currency and Currency Translation

Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.

The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.

Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018 and does not anticipate that this guidance will materially impact its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company has adopted this guidance.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company intends to adopt this standard on January 1, 2017 and does not anticipate that this guidance will materially impact its consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company intends to adopt this standard on January 1, 2017 and does not anticipate that this guidance will materially impact its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. As of December 31, 2016, the Company has early adopted ASU 2016-09. The cumulative-effect adjustment to equity related to the recognition of excess tax benefits (offset by valuation allowance) is discussed in Note 13.

In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

Inventories

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories

(2)

Inventories

Inventories consist of the following:


(in thousands)	September 30, 2017		December 31, 2016
Raw materials	$	328	$	346
Work-in-process		660		214
Finished goods		176		100

Total inventories	$	1,164	$	660

(4)

Inventories

Inventories consist of:


	December 31,		December 31,
(in thousands)	2016		2015
Raw materials	$	346	$	360
Work-in-process		214		251
Finished goods		100		146

Total Inventory	$	660	$	757

Prepaid Expenses and Other Current Assets

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

(3)

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


(in thousands)	September 30, 2017		December 31, 2016
Insurance premiums	$	61	$	501
Taxes		53		—
Security Deposit		50		50
Other¹		221		147

Total prepaid expenses and other current assets	$	385	$	698

1	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at September 30, 2017 and December 31, 2016.

(5)

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets include the following:


	December 31,		December 31,
(in thousands)	2016		2015
Insurance premiums	$	501	$	625
Kits for clinical use		—		162
Other		197		173

Total prepaid expenses and other current assets	$	698	$	960

Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2016 and 2015.

Property, Plant, and Equipment

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property, Plant, and Equipment

(4)

Property, Plant, and Equipment

Property, plant, and equipment consist of the following:


(in thousands)	September 30, 2017			December 31, 2016
Buildings and land	$	574		$	556
Enterprise hardware and software		1,648			1,532
Leaseholds		1,659			1,504
Equipment		960			940
Furniture		182			354

Property, plant and equipment, gross		5,023			4,886
Accumulated depreciation		(3,770	)		(3,803	)

Property, plant and equipment, net	$	1,253		$	1,083

Depreciation expense for the three and nine months ended September 30, 2017 was approximately $0.1 million and $0.2 million, respectively, as compared to approximately $0.1 million and $0.2 million, respectively, for the same periods in 2016.

(6)

Property, Plant, and Equipment

Property, plant, and equipment consists of:


	December 31,			December 31,
(in thousands)	2016			2015
Buildings and land	$	556		$	556
Enterprise hardware and software		1,532			1,520
Leaseholds		1,504			1,305
Equipment		940			902
Furniture		354			355

Property, plant and equipment, gross		4,886			4,638
Accumulated depreciation		(3,803	)		(3,506	)

Property, plant and equipment, net	$	1,083		$	1,132

Depreciation expense for the years ended December 31, 2016 and 2015 was $0.3 million and $0.6 million, respectively.

Accrued Expenses

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Payables and Accruals [Abstract]

Accrued Expenses

(5)

Accrued Expenses

Accrued expenses consist of the following:


(in thousands)	September 30, 2017		December 31, 2016
Clinical trial expenses	$	1,410	$	1,365
Compensation, excluding taxes		1,132		933
Professional fees		448		286
Short-term portion of lease restructuring		221		216
Other¹		544		607

Total accrued expenses	$	3,755	$	3,407

1	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

(7)

Current Accrued Expenses

Current accrued expenses include the following:


	December 31,		December 31,
(in thousands)	2016		2015
Clinical trial expenses	$	1,365	$	692
Compensation, excluding taxes		933		391
Professional fees		286		220
Short-term portion of lease restructuring		216		219
Other		607		721

Total accrued expenses	$	3,407	$	2,243

Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2016 and 2015.

Restructuring Expenses

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Restructuring and Related Activities [Abstract]

Restructuring Expenses

(6)

Restructuring Expenses

In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of September 30, 2017, the total remaining lease restructuring liability for its leased office space was approximately $0.7 million, of which approximately $0.3 million and $0.4 million were included in Accrued expenses and Other non-current liabilities on the condensed consolidated balance sheets, respectively.

The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017:


(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(155	)

Reserve balance at September 30, 2017	$	665

(8)

Restructuring Expenses

In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of December 31, 2016, the total remaining lease restructuring liability for its leased office space was approximately $0.8 million, of which approximately $0.2 million and $0.6 million were included in Accrued expenses and Other non-current liabilities on the consolidated balance sheets, respectively.

The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2016:


(in thousands)	Lease Liability
Reserve balance at December 31, 2015	$	1,039
Charges		—
Payments/Utilizations		(219	)

Reserve balance at December 31, 2016	$	820

Convertible Notes Payable

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Debt Disclosure Abstract

Convertible Notes Payable

(7)

Convertible Notes Payable

On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes are secured pursuant to a Security Agreement which creates a first priority security interest in all of the personal property (other than Excluded Collateral (as defined in the Security Agreement) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future.

The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default.

Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. An additional $6.6 million was released during the three months ended March 31, 2017. Under the terms of warrant repurchase agreements signed in April 2017 and discussed in more detail below, $7.9 million was returned to the holders in exchange for the extinguishment of the Series C Warrants. During the three months ended September 30, 2017, an additional $2.1 million was released to the Company and $2.4 million was returned to the holders in order to redeem the Series A and Series B Preferred Shares discussed in more detail in Note 8. The remaining cash proceeds of $7.3 million are being held in restricted accounts.

In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire appoximately 20,000 shares of Common Stock. The provisions in the Series C Warrants required the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. On April 2, 2017 the Company entered into separate warrant repurchase agreements (the “Warrant Repurchase Agreements”) with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case were paid to the respective investor, in exchange for cancellation of the Warrants issued to each investor under the SPA. As a result of the extinguishment, the Company recognized a gain of $9.6 million, representing the difference between the fair value of the liability as of the extinguishment date of $17.5 million related to the Series C Warrants and the $7.9 million in cash returned to the Note holders to extinguish the liability.

The Company has agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. If we cannot meet the equity conditions, we could be required to repay some or all of the amounts due under the notes in cash, and we may not have the funds available to make one or more of such payments when due. At any time after the issuance of the Notes, the Notes will be convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $1,536.50, subject to adjustment as provided in the Notes.

Restructuring Agreement

On August 28, 2017, the Company entered into a Restructuring Agreement (the “Agreement”) with one of the institutional investors (the “Investor”) who was a party to the SPA. As of the date the Agreement was entered into, the Investor held $11,444,637 aggregate principal amount of Notes of which there was $10,092,857 aggregate Restricted Principal, (as defined in the Notes) of Notes (the “Restricted Notes”), secured by such aggregate cash amount held in a collateral account of the Company in the same amount (the “Restricted Cash”) and (y) $1,351,780 principal of Notes (the “Unrestricted Notes”), (ii) 4,200 shares of Series A Preferred Stock and (iii) 2,006 shares of Series B Convertible Preferred Stock.

Pursuant to the Agreement, (a) on the date thereof the Company and the Investor took the following actions (the “Initial Restructuring”): (i) the Investor released restrictions on $1,650,000 of Restricted Cash (the “Initial Release”), (ii) the Investor consented to the use of additional Restricted Cash to effect redemptions of the Series A Preferred Shares and the Series B Preferred Shares, (iii) the Investor cancelled $1,200,000 aggregate principal of the Notes (such portion of the Notes, the “Cancellation Note”), (iv) the Company redeemed all the Series A Preferred Shares outstanding for a cash payment to the Investor of $4.20 and (v) the Company redeemed the Series B Preferred Shares for a cash payment to the Investor of $2,006,000 and (b) upon the consummation of a reverse stock split of our Common Stock of at least twenty to one (the “Reverse Stock Split Event”, and such date, the “Reverse Stock Split Date”) by September 15, 2017, the Company and the Investor shall have taken the following actions (the “Additional Restructuring”, and together with the Initial Restructuring, the “Restructuring”): (i) the Investor shall consent to the use of Restricted Cash to effect redemptions of $4,000,000 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Redemption Notes”), (ii) the Company shall redeem the Redemption Notes for a redemption price of $6,436,852.80 (the “Redemption Price”) and (iii) the Company shall exchange (the “Exchange”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, $2,436,852.80 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Exchange Notes”, and together with the Redemption Notes, the “Restructured Notes”) for new warrants to purchase 114,286 shares of its Common Stock (the “New Warrants”, as exercised, the “New Warrant Shares”). The New Warrants expire on the 42 month anniversary of the date of issuance and bear an exercise price of $122.50 per share (which shall be adjusted to the new lower purchase price per share if there is a subsequent “down round” financing). The Investor, in lieu of an exercise of the New Warrants pursuant to a cash payment of the aggregate exercise price of the number of New Warrants being exercised, may exercise the New Warrants, in whole or in part, by electing instead to receive upon such exercise two shares and one hundred and twenty-five thousandths of a share of the Company’s Common Stock for each Warrant Share exercised pursuant to this provision The transactions set forth herein were being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 144(d)(3)(ii) of the 1933 Act. As a result of not having effected a reverse stock split by September 15, 2017, the Additional Restructuring did not occur.

Amendment to Restructuring Agreement

As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,551 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments.

The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:


	Number of		Number of		Applicable
	Shares of		Shares of		Conversion		Reduction in
	Common Stock		Preferred Stock		Price		Principal
January 12, 2017		11,753		—	$	126.00	$	1,478,318
January 26 - February 1, 2017¹		4,857		—	$	112.00		544,000
February 10, 2017		43,882		—	$	70.00		3,045,817
February 23 - March 2, 2017¹		2,571		—	$	49.00		126,000
March 13, 2017		117,297		—	$	38.50		4,417,830
April 10, 2017		169,061		—	$	21.00		3,621,286
May 9, 2017		109,367		—	$	17.50		1,913,915
June 7 / July 2, 2017 Exchange Agreement²		689,796		4,200	$	6.09		4,200,000
July 7, 2017		114,286		—	$	17.50		2,000,000
August 4, 2017		38,906		—	$	24.50		1,015,848
August 28, 2017 Restructuring Agreement³		117,171		—	$	10.50		1,200,000

Total		1,418,948					$	23,563,014

¹	During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof.

On July 2, 2017, the Company entered into an exchange agreement with one of its investors which had purchased Notes, for $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock. The Series A Preferred Stock shares were issued to address a short-term valuation issue for 689,796 common shares delivered to the Notes holders to close an installment period. Through the Series A Preferred Shares placement, the Company was able to value the open installment shares such that the amount of debt remaining under the Notes was reduced by $4.2 million. Additionally, the Company recognized a loss on debt settlement of $1.0 million related to this transcation.

On August 28, 2017, the Company entered into a restructuring agreement with one of its investors which had purchased Notes. The restructuring agreement included a provision to exchange 117,171 shares for $1.2 million aggregate principal amount of such Notes. Additionally, the Company recognized a loss on debt settlement of $2.0 million related to this transaction. The restructuring agreement is discussed in more detail above.

As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants, the Company has recognized a beneficial conversion feature of $4.4 million. The original issue discount, the beneficial conversion feature, and the fair value of the issuance of the Series C Warrants are collectively considered the debt discount. The Company recorded a debt discount in the amount of $35.0 million which is being amortized over the life of the Notes using the effective interest method. As of September 30, 2017, $33.3 million of the debt discount has been amortized to interest expense. In addition to the debt discounts listed above, the Notes also include put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at September 30, 2017.

All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. As of September 30, 2017, the Company had incurred approximately $1.8 million in debt issuance costs and had amortized approximately $1.2 million of those costs.

The following table summarizes the convertible notes outstanding at September 30, 2017:


(in thousands)
Convertible notes payable, principal	$	11,437
Debt discounts		(1,701	)

Net convertible note payable	$	9,736

(9)

Convertible Notes Payable

On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes are secured pursuant to a Security Agreement which creates a first priority security interest in all of the personal property (other than Excluded Collateral (as defined in the Security Agreement)) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future.

The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default (as defined in the SPA), at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default.

Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. The remaining cash proceeds of $26.2 million are being held in a restricted account and will be released to the Company in subsequent tranches subject to certain equity conditions.

As security for the Company’s obligations under the Notes, $26.2 million of the total net cash proceeds is subject to a cash covenant restricting its use and requiring it to be held in a Master Restricted Account established in accordance with and pursuant to the terms and conditions of an account control agreement between the Company, the Buyers and Silicon Valley Bank (a “Controlled Account Agreement”). Subject to certain equity conditions, the $26.2 million of restricted cash will become unrestricted in equal quarterly installments during 2017, such that the balance will become unrestricted by the maturity date of the Notes, December 29, 2017, subject to satisfaction of certain equity conditions contained in the Notes.

In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire 6.8 million shares of Common Stock. On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events).

Each Series C Warrant will be exercisable by the holder beginning June 13, 2017 and continuing for a period of five years thereafter. The Series C Warrants are exercisable at $4.83 per share of common stock, subject to adjustments for certain dilutive events. The provisions in the Series C Warrants require the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants.

The Company has agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. If we cannot meet the equity conditions, we could be required to repay some or all of the amounts due under the notes in cash, and we may not have the funds available to make one or more of such payments when due. At any time after the issuance of the Notes, the Notes will be convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $4.39, subject to adjustment as provided in the Notes.

As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants, the Company has recognized a beneficial conversion feature of $4.4 million. The original issue discount, the beneficial conversion feature, and the fair value of the issuance of the Series C Warrants are collectively considered the debt discount. The Company recorded a debt discount in the amount of $35.0 million which is being amortized over the life of the Notes using the effective interest method. As of December 31, 2016, $14.0 million of the debt discount has been amortized to interest expense. In addition to the debt discounts listed above, the Notes also include put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at December 31, 2016.

All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. As of December 31, 2016, the Company had incurred approximately $1.0 in debt issuance costs and had amortized approximately $0.3 million of those costs.

The following table summarizes the convertible notes outstanding at December 31, 2016:


(in thousands)	December 31, 2016
Convertible notes payable, principal	$	34,351
Debt discounts		(21,008	)

Net convertible note payable	$	13,343

In 2016, the Company issued 1.8 million shares as payment for $0.6 million of convertible notes payable.

Stockholders' Equity

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Stockholders Equity Note Abstract

Stockholders' Equity

(8)

Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-three hundred fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.]

On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares.

Recent Preferred Stock Issuances

Series A Preferred Stock

On June 29, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series A Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the

“Series A Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series A Preferred Stock”). On July 2, 2017, we entered into an exchange agreement (the “Exchange”) with one of our investors which had purchased certain senior secured convertible notes (the “Notes”), convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock (the “Series A Preferred Shares”). The Exchange was made in reliance upon the exemption from registration provided by Rule 3(a)(9) of the Securities Act of 1933, as amended. The Series A Preferred Shares were entitled to the whole number of votes equal to $4.2 million divided by $1,288.00 (the closing bid price on June 13, 2016, the date of issuance of the Notes as adjusted for the reverse stock split effected in July 2016,) or 3,261 votes. The Series A Preferred Stock had no dividend, liquidation or other preferential rights to our common stock, and each share of Series A Preferred Stock was redeemed for the amount of $0.001, paid in cash pursuant to the Restructuring Agreement signed on August 28, 2017 and discussed in further detail in Note 7.

Series B Preferred Stock

On June 29, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series B Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series B Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series B Preferred Stock”). On July 11, 2017, we entered into a securities purchase agreement with existing holders of Notes pursuant to which the investors purchased $2,360,000 of Series B Preferred Stock for a cash purchase price of $2,000,000 in a private placement. The Series B Preferred Stock was entitled to the whole number of votes equal to $2.0 million divided by $65.35 (the closing bid price on July 5, 2017, the date of the original securities purchase agreement for the Series B Preferred Stock), or 30,607 votes. The Series B Preferred Stock had no dividend, liquidation or other preferential rights (but had the redemption rights described below) to our common stock and could have been converted into shares of our common stock at a price equal to $53.55 per share upon the earlier of the date of closing to the extent that the holder thereof reallocated shares of our common stock reserved for issuance under its Notes to conversion of the Series B Preferred Shares and otherwise upon receipt of shareholder approval of the Reverse Stock Split. The Series B Preferred Stock allowed for optional redemption by the Company at any time after issuance or the holders at any time after the tenth business day prior to the maturity date. In the instance of a Financing, the Company was required to redeem the Series B Preferred Stock. The $360,000 difference between the redemption amount and the cash purchase price of the Series B Preferred Stock, as well as all issuance costs related to the Series B Preferred Stock, have been recorded as a deemed dividend. The Series B Preferred Stock was redeemed for $2,360,000 pursuant to the Restructuring Agreement signed on August 28, 2017 with one investor and upon a redemption notice from the second investor as discussed in further detail in Note 7.

Series C Preferred Stock

On September 12, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series C Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock which was filed with the State of Delaware on September 20, 2017. On September 21, 2017, we entered into a securities purchase agreement with two of our investors which had purchased Notes, convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $0.5 million aggregate purchase price for 590 shares of Series C Preferred Stock. The purchase of the Series C Preferred Stock is being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended. The Series C Preferred Stock shall be entitled to 1,484,061 votes and may only vote on approval of a reverse split of our outstanding common stock. The Series C Preferred Stock has no dividend, liquidation or other preferential rights to our common stock, and each share of Series C Preferred Stock shall be redeemable for the amount of $1,000.00, payable in cash per share at our written election, and must be redeemed by us no later than December 21, 2017. Because the Series C Preferred Stock is mandatorily redeemable, it has been recorded as a liability with the difference between the purchases price and the fair value being recognized over the term of the instrument. Additionally, all expenses related to the issuance of the Series C Preferred Stock are recognized as a debt discount and have been amortized over the term of the instrument. Per the terms of the October 22, 2017 Amendment to the Restructuring Agreement, the Series C Preferred Stock was redeemed for $590,000 on November 6, 2017.

Warrants

In October 2013, the Company completed the sale of 234 shares of its common stock and the issuance of warrants to purchase approximately 106 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is

subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At September 30, 2017, the 2013 Warrants were exercisable at $39,424.00 per share with approximately 100 warrants outstanding. The 2013 Warrants have a five-year term.

In February 2015, the Company completed the sale of approximately 440 shares of its common stock and the issuance of warrants to purchase 197 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2017, the February 2015 Warrants were exercisable at $49.00 per share with approximately 100 warrants outstanding. The February 2015 Warrants have a five-year term.

In July 2015, the Company completed the sale of approximately 1,715 Units consisting of approximately 1,715 shares of its common stock, Series A Warrants to purchase up to approximately 1,140 common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 1,715 common shares (“Series B Warrants”) and 1,140 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the three months ended March 31, 2016, approximately 285 Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 1,140 Series B Warrants expired on January 29, 2016 and the remaining liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 285 Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2017, the Series A Warrants were exercisable at $49.00 with approximately 500 warrants outstanding. The Series A Warrants have a five-year term. There were approximately 285 July 2015 Series A Warrants exercised during the nine months ended September 30, 2017 for proceeds of approximately $15,000.

In October 2016, the Company completed the sale of approximately 1,215 shares of its common stock and the issuance of warrants to purchase 425 common shares (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At September 30, 2017, the October 2016 Warrants were exercisable at $49.00 per share with 200 warrants outstanding. The October 2016 Warrants have a five-year term.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 34 and 573 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 304 shares, from 269 to 573 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of September 30, 2017 there were 55 shares available to grant under the 2009 Stock Incentive Plan.

A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant.

For the three and nine months ended September 30, 2017, the Company recognized compensation expense of approximately $3,000 and $48,000, respectively, relating to stock options granted to employees. For the same periods in 2016, the Company recognized compensation expense of approximately $24,000 and $0.1 million, respectively. There were 43 stock options awards granted during the nine months ended September 30, 2017. There were no stock option awards granted during the same period in 2016.

For the three and nine months ended September 30, 2017, the Company recognized compensation expense of approximately $20,000 and $0.1 million, respectively, relating to restricted stock granted to employees. For the same periods in 2016, the Company recognized compensation expense of approximately $38,000 and $0.2 million, respectively. There were 264 shares of restricted stock granted during the nine months ended September 30, 2017. There were approximately no shares of restricted stock awards granted for the same period in 2016.

(10)

Stockholders’ Equity

Reverse Stock Split

(1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

Stock and Warrant Issuances

In October 2013, the Company completed the sale of 81,875 shares of its common stock and the issuance of warrants to purchase approximately 37,000 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2016, the 2013 Warrants were exercisable at $112.64 per share with 36,848 warrants outstanding. The 2013 Warrants have a five-year term.

In February 2015, the Company completed the sale of 153,750 shares of its common stock and the issuance of warrants to purchase 69,000 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2016, the February 2015 Warrants were exercisable at $1.61 per share with approximately 30,238 warrants outstanding. The February 2015 Warrants have a five-year term. There were approximately 40,000 February 2015 Warrants exercised during the year ended December 31, 2016 for proceeds of approximately $0.1 million.

In July 2015, the Company completed the sale of approximately 0.6 million Units consisting of 0.6 million shares of its common stock, Series A Warrants to purchase up to approximately 0.4 million common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 0.6 million common shares (“Series B Warrants”) and 0.4 million Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the year ended December 31, 2016, approximately 0.1 million Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 0.4 million Series B Warrants expired on January 29, 2016 and the related liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 0.1 million Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2016, the July 2015 Series A Warrants were exercisable at $1.61 with approximately 0.3 million warrants outstanding. The Series A Warrants have a five-year term. There were approximately 0.3 million July 2015 Series A Warrants exercised during the year ended December 31, 2016 for proceeds of $0.4 million.

In June 2016, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued $35.0 million in principal face amount of the Notes and related Series C Warrants to purchase 6.8 million additional shares of the Company’s common stock. The Company allocated an estimated fair value of $27.8 million to the Series C Warrants. On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events). The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2016, The Series C Warrants were exercisable at $4.83 with approximately 6.8 million warrants outstanding. The Series C Warrants will be exercisable by the holder beginning one year after the closing date and continuing for a period of five years thereafter.

In October 2016, the Company completed the sale of 425,000 shares of its common stock and the issuance of warrants to purchase 148,750 common shares (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2016, the October 2016 Warrants were exercisable at $1.61 per share with 78,750 warrants outstanding. The October 2016 Warrants have a five-year term. There were 70,000 October 2016 Series C Warrants exercised during the year ended December 31, 2016 for proceeds of $0.1 million.

In October 2015, the Company filed a registration statement on Form S-3 with the SEC, which was declared effective on October 20, 2015 and allows the Company to offer and sell, from time to time in one or more offerings, up to $77.4 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. Pursuant to SEC regulations, so long as the Company’s public float remains below $75 million, we cannot sell securities from the shelf registration statement which represent more than one third of the market value of our non-affiliated public float during any 12-month period.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 11,719 and 200,391 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 106,250 shares, from 94,141 to 200,391 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of December 31, 2016, there were 120,883 shares available to grant under the 2009 Stock Incentive Plan.

Stock option activity for 2016 and 2015 is as follows:


	Stock Option Activity under the Plans
								Weighted Average
				Exercise Price per		Weighted Average		Remaining Life
	Stock Options			Share		Exercise Price		(Years)
Outstanding at December 31, 2014		17,577		$	19.84 - $3,921.92	$	378.08		8.83
Granted		32,765			19.04		19.04
Forfeited		(3,121	)		19.04 - 2,713.60		480.16

Outstanding at December 31, 2015		47,221			19.04 - 3,921.92	$	122.40		8.95

Granted		—			—		—
Forfeited		(5,865	)	$	19.04 - $545.28		23.95

Outstanding at December 31, 2016		41,356		$	19.84 - $3,788.80	$	135.77		7.90

Exercisable at December 31, 2016		26,774		$	19.04 - $3,788.80	$	199.31		7.63

For the years ended December 31, 2016 and 2015 the Company recognized compensation expense related to stock option grants of approximately $0.2 million and $0.3 million, respectively.

The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the year ended December 31, 2015. There were no option grants during the year ended December 31, 2016:


	Year ended December 31, 2015
Weighted average risk-free interest rates		1.82	%
Weighted average expected volatility		97.70	%
Dividend yield		—
Weighted average expected option term (in years)		5.15
Weighted average grant date fair value	$	0.89

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during 2015, 2014, 2013 and the second half of 2012 is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized because the Company did not have sufficient historical experience from which to estimate the period.

A summary of the Company’s non-vested options to purchase shares as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below:


	Non-Vested Options
				Weighted
	Number of			Average
	Options			Exercise Price
Non-vested at January 1, 2015		14,116		$	332.16
Granted		32,765			28.48
Vested		(9,994	)		421.60
Forfeited		(1,416	)		574.72

Non-vested at December 31, 2015		35,471		$	22.55
Granted		—			—
Vested		(15,671	)		26.85
Forfeited		(5,218	)		19.23

Non-vested at December 31, 2016		14,582		$	19.11

Additional compensation expense of approximately $55,000, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 1.06 years.

The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2016 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $0.92 as of December 31, 2016, which would have been received by the option holders had those option holders exercised their options as of that date.

A summary of the Company’s restricted stock activity as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below:


	Restricted Stock Activity
				Weighted
				Average
	Number			Grant Date
	of Shares			Fair Value
Non-vested at January 1, 2015		1,857		$	269.44
Granted		36,000			41.60
Vested		(1,854	)		217.60
Forfeited		(8	)		54.40

Non-vested at December 31, 2015		35,995		$	19.04
Granted		4,687			4.32
Vested		(19,189	)		15.44
Forfeited		(2,500	)		19.04

Non-vested at December 31, 2016		18,993		$	19.04

For the years ended December 31, 2016 and 2015 the Company recognized compensation expense related to restricted stock grants of approximately $0.3 million and $0.3 million, respectively. Additional compensation expense of $0.1 million relating to the unvested portion of restricted stock granted is expected to be recognized over a remaining average period of 1.12 years.

Warrants

The Company issued warrants as part of its offerings in 2013, 2015, and 2016, as well as part of its issuance of convertible notes in 2016. A summary of warrant activity is as follows:


						Weighted		Weighted
						Average		Average
				Exercise Price		Exercise		Remaining
	Warrants			per Share		Price		Life (Years)
Outstanding at January 1, 2014		53,134			28.00-112.64	$	86.69		2.78
Issued		1,091,844					12.80
Exercised		(13,457	)				13.12
Expired		(2,833	)				13.12

Outstanding at December 31, 2015		1,128,688			11.84-112.64	$	16.02		2.16
Issued		7,031,929					4.80
Exercised		(499,633	)				2.75
Expired		(444,964	)				5.68

Outstanding at December 31, 2016		7,216,020			1.61-112.64	$	5.20		5.59

Fair Value Measurements

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

(9)

Fair Value Measurements

Derivative Warrant Liability

As disclosed in Note 8 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes discussed in further detail in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. The valuation of the October 2013, February 2015, July 2015 Series A, June 2016 Series C and October 2016 warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the three and nine months ended September 30, 2017, the Company recorded pre-tax derivative warrant income of approximately $27,000 and $1.2 million, respectively. The resulting derivative warrant liabilities totaled approximately $16,000 at September 30, 2017. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions:


	October 2016 Warrants			July 2015 Series A Warrants			February 2015 Warrants			October 2013 Warrants
Expected volatility		142.46	%		165.32	%		181.24	%		227.68	%
Risk-free interest rates		1.77	%		1.59	%		1.53	%		1.33	%
Expected life (in years)		4.02			2.81			2.38			1.08

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820.


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
							Balance at
							September 30,
(in thousands)	Level 1		Level 2		Level 3		2017
Liabilities
Derivative instrument liabilities	$	—	$	—	$	16	$	16

For the periods ended September 30, 2017 and 2016, there were no transfers in or out of Level 1, 2 or 3 inputs.

The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(1,227	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		—
Fair value of warrants exercised		(19	)

Balance at September 30, 2017	$	16

(11)

Fair Value Measurements

Derivative Financial Instruments

As disclosed in Note 10 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes discussed in further detail in Note 9 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K. The valuations of the October 2013, February 2015, July 2015 Series A, June 2016 Series C, and October 2016 Warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the year ended December 31, 2016, the Company recorded pre-tax derivative instrument income of $12.8 million. The resulting derivative instrument liabilities totaled $18.8 million at December 31, 2016. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2016 was determined by using option pricing models assuming the following:


	October			June 2016			July 2015			February			October
	2016			Series C			Series A			2015			2013
	Warrants			Warrants			Warrants			Warrants			Warrants
Expected volatility		95.03	%		94.19	%		95.51	%		95.52	%		152.70	%
Risk free interest rates		1.93	%		2.01	%		1.59	%		1.47	%		1.20	%
Expected life (in years)		4.80			5.50			3.60			3.10			1.80

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016 and 2015, aggregated by the level in the fair value hierarchy within which those measurements fall.

Assets and Liabilities Measured at Fair Value on a Recurring Basis


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
													Balance at
	Level 1				Level 2				Level 3				December 31,
(in thousands)	2016		2015		2016		2015		2016		2015		2016		2015
Liabilities
Derivative instrument liabilities	$	—	$	—	$	—	$	—	$	18,751	$	3,785	$	18,751	$	3,785

Fair Value Measurements Using Significant Unobservable

Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at January 1, 2015	$	225
Total change in the liability included in earnings		(564	)
Fair value of warrants issued		4,247
Fair value of warrants exercised		(123	)

Balance at December 31, 2015		3,785
Total change in the liability included in earnings		(12,780	)
Fair value of warrants issued		28,472
Fair value of warrants exercised		(726	)

Balance at December 31, 2016	$	18,751

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments

(12)

Commitments

Operating Leases

In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space at 810 Seventh Avenue, New York, NY with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010. In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Initial Lease and the Lease Amendment provide for annual rent of $996,000 in 2015, $1.0 million in 2016, and $1.1 million in 2017-2020. As discussed in Note 8, the Company has sub-leased this office space.

In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August 2, 2011. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The annual lease amounts, which escalate annually, are as follows (USD conversions are based on the December 31, 2016 conversion rate): Year 1 – €106,051 ($115,458), Year 2 –

€134,974 ($146,946), Year 3 – €159,077 ($173,187) and Years 4 and 5 – €183,179 ($199,427). Annual lease amounts in years 6 through 10 are to be paid at a fixed amount of €187,209 ($197,377). Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath. The Company has sub-leased a portion of this facility.

In March 2016, the Company entered into a sub-lease agreement to lease approximately 6,877 square feet of office space at 1633 Broadway, New York, NY. The term began in April 2016 and is effective through March 2019. The agreement provides for total annual base rent of $522,652.

In October 2016, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on November 1, 2016 and was effective for a two year period. The agreement provides for total annual base rent of $48,223 and will expire October 2018.

Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2016 are as follows:


	Future Lease
(in thousands)	Payment
2017	$	952
2018		946
2019		529
2020		428
2021		254
2022		—

	$	3,109

Rent expense totaled approximately $0.5 million and $0.4 million, for the years ended December 31, 2016 and 2015, respectively.

Letters of Credit

Under the terms of the lease agreement for office space at 810 Seventh Avenue, New York, NY, the Company is required to maintain a letter of credit in the amount of $881,297 which will expire in February 2017 if not renewed by the Company. Under the terms of a sub-lease agreement for office space at 1633 Broadway, New York, NY, the Company is required to maintain a letter of credit in the amount of $130,663 which will expire with the sublease in March 2019.

Income Taxes

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

(11)

Taxes

As discussed in Note 13 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. During the third quarter of 2015, the Internal Revenue Service commenced an examination of the Company’s federal income tax return for the year ended December 31, 2013. The examination was completed in the third quarter of 2017 and no changes were made to the reported amounts. Accordingly, there was no effect on the financial statements as a result of the examination. The Company has not been audited by the international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

(13)

Income Taxes

There is no income tax provision for the years ended December 31, 2016 and 2015. Income before income taxes consists of:


	Year Ended December 31,
(in thousands)	2016			2015
Domestic	$	(13,930	)	$	(11,276	)
Foreign		(4,040	)		(3,428	)

Income before taxes	$	(17,970	)	$	(14,704	)

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:


	Year Ended December 31,
(in thousands)	2016			2015
Income taxes using U.S federal statutory rate	$	(6,110	)	$	(4,999	)
Loss of tax benefit of net operating loss carryforwards		68,795			—
Loss of tax benefit of state net operating loss carryforwards		13,891			—
Loss of tax benefit of tax credit carryforwards		4,023			—
Amortization of gain on IP migration		767			767
State income taxes, net of federal benefit		(2,576	)		380
Foreign rate differential		1,141			920
Valuation allowance		(75,407	)		2,649
Derivative charge		(4,345	)		(192	)
Stock option exercises and cancellations		53			674
Research and development costs		(250	)		(199	)
Other		18			—

	$	—		$	—

Significant components of the Company’s deferred tax assets are as follows:


(in thousands)	December 31, 2016		December 31, 2015
Deferred tax assets:
Employee compensation accruals	$	1,386	$	1,279
Accrued liabilities		343		633
Research tax credits		22		3,796
Other		55		66
Net operating losses		6,194		77,906

Total deferred tax assets	$	8,000	$	83,680

Deferred tax liabilities:
Beneficial conversion feature		906		—

Total deferred tax liabilities	$	906	$	—

Valuation allowance		7,094		83,680

Net deferred tax assets	$	—	$	—

As of December 31, 2016 and 2015, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $209.3 million and $184.5 million, respectively. A significant portion of the federal amount, $201.0 million, is subject to an annual limitation of approximately $72,500 as a result of a change in the Company’s ownership in May 2003 and November 2016, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitations caused by the May 2003 and November 2016 ownership changes, approximately $205.7 million of the total net operating loss carryforwards is expected to expire unutilized and will be unavailable to offset future federal taxable income. Approximately $3.6 million of net operating loss carryforwards remains available to offset future federal taxable income which will expire between 2018 and 2036. In addition, the Company’s state net operating losses are also subject to annual limitations that generally follow the federal Section 382 provisions, adjusted for each state’s respective income apportionment percentages. As of December 31, 2016 and 2015, the Company had net operating loss carryforwards for state and city income tax purposes between approximately $27.3 million and $153.0 million and between approximately $27.3 million and $109.7, respectively, which expire through 2036. As a result of the 382 limitations, approximately $150.2 million and $130.5 million of New York State and New York City net operating losses are expected to expire unutilized and will be unavailable to offset future taxable income. Approximately $2.8 million and $2.7 million of net operating loss carryforwards, respectively, will be available to offset future state and city taxable income. As of December 31, 2016 and 2015, the Company had a net operating loss

carryforward for foreign income tax purposes of $21.1 million and $22.1 million, respectively, which have indefinite carryforward periods. As of December 31, 2016 and 2015, the Company had federal research and development tax credit carryforwards of approximately $4.0 million and $3.8 million, respectively, which expire through 2036. As a result of the section 382 limitation, the entire tax credit carryforward is expected to expire unutilized.

The Company has a tax benefit of approximately $1.0 million related to the exercise of non-qualified stock options. As a result of the adoption of ASU 2016-09, the $1.0 million tax benefit was recognized as a cumulative adjustment to retained earnings, offset by a $1 million valuation allowance against retained earnings.

Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company’s valuation allowance decreased by approximately $76.6 million and increased by approximately $2.6 million in 2016 and 2015, respectively. The primary reason for the significant decrease in the valuation allowance during the current year is due to the reduction of recognizable deferred tax assets related net operating loss and credit carryforwards resulting from the Sec. 382 ownership change. The change in valuation allowance is as follows:


(in thousands)	December 31, 2016			December 31, 2015
Beginning balance	$	83,680		$	81,223
Charged to costs and expenses		(75,407	)		2,649
Charged to additional paid-in capital		(1,854	)		—
Charged to retained earnings		1,010			—
Charged to other comprehensive income		(335	)		(192	)

Ending balance	$	7,094		$	83,680

The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company is currently under examination by the Internal Revenue Service for the period ending December 31, 2013. The examination commenced in the third quarter of 2015 and as of December 31, 2016, there have been no adjustments proposed. The Company has not recorded an uncertain tax position and therefore a table of unrecognized tax benefits has not been presented, and no interest or penalties have been accrued as of December 31, 2016. The Company’s total amount of unrecognized tax benefits could increase within the next twelve months as a result of the exam. However, the effect of the outcome cannot be reasonably estimated as the IRS examination is ongoing. The Company has not been audited by any state tax authorities in connection with income taxes. The Company has not been audited by international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company is no longer subject to federal and state examination for tax years ending prior to December 31, 2013; tax years ending December 31, 2013 through December 31, 2016 remain open to examination. However, the Company’s tax years December 31, 1998 through December 31, 2016 generally remain open to adjustment for all federal, state and foreign tax matters until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization, and the applicable statutes of limitation have expired in the utilization year. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Subsequent Events

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

(12)

Subsequent Events

As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,550 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments.

The exercise price for the warrants issued in conjunction with the amended restructuring agreement is $122.50. The warrants contain a cashless exercise provision pursuant to which the warrants may be exercised for 382,650 shares of the Company’s common stock on or after the 75th day subsequent to the date of consummation of offering hereunder. On the 136th day subsequent to the date of consummation of the offering hereunder, there shall be a “true up” with regard to the issuance of shares upon exercise such that the difference between 382,650 shares and the number of shares that would be issuable if the exercise price were lowered to the average price per share of the variable weighted average price of our common stock for the five trading days commencing on the date which is 76 days after the date of consummation of the offering hereunder, but not lower than 33% of the variable weighted average price of a share of our common stock on the 81st date following the date of consummation of the offering hereunder. In lieu of the “true up”, on or before the 135th date following the date of consummation of the offering hereunder, we may buy out that provision for $6,138,349.80.

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

(14)

Subsequent Events

NASDAQ Notification Letter

On February 13, 2017, the Company received a notification letter (the “Notice”) from The NASDAQ Stock Market (“NASDAQ”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Notice stated that the Company will be provided 180 calendar days, or until August 14, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company’s common stock must close at or above $1.00 per share for a minimum of ten consecutive business days prior to that date. If, by August 14, 2017 the Company cannot demonstrate compliance with Marketplace Rule 5550(a)(2), then the NASDAQ staff will determine whether or not the Company meets The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 5550, except for the bid price requirement. If the Company meets the initial listing criteria (with the exception of the bid price requirement) and provides written notice of its intention to cure the deficiency during an additional 180 calendar day compliance period, the NASDAQ staff will notify the Company that it has been granted such an additional compliance period (the “second compliance period”). If the Company is not eligible for the second compliance period, the NASDAQ staff will provide written notice that the Company’s securities will be delisted. At that time, the Company may appeal the NASDAQ staff’s determination to delist its securities to a Listing Qualifications Panel.

From January 1, 2017 through March 28, 2017, the Company issued 109,345,554 shares of Common Stock to the holders of the Notes as payment on the convertible notes payable.

From January 1, 2017 through March 28, 2017, the holders of Notes released an aggregate of approximately $6.6 million in cash previously funded to the Company and authorized the release of those funds from the restricted accounts of the Company in accordance with the Master Control Account Agreement.

General

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

(1)

General

The interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and nine months ended September 30, 2017 and 2016 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”), which has been filed with the Securities Exchange Commission (“SEC”), as amended by that certain Amendment No. 1 to Form 10-K for the year ended December 31, 2016, filed with the SEC on July 14, 2017 and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

Description of Business

Our primary research focus is on ocular melanoma liver metastases (mOM) and intrahepatic cholangiocarcinoma (ICC), a type of primary liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need.

Our clinical development program for CHEMOSAT and Melphalan/HDS is comprised of The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial), a Global Phase 3 clinical trial that is investigating overall survival in mOM, and a registration trial for intrahepatic cholangiocarcinoma (ICC) we plan to initiate in 2017. Our clinical development plan (CDP) also includes a commercial registry for CHEMOSAT non-clinical commercial cases performed in Europe and sponsorship of select investigator initiated trials (IITs) in colorectal cancer metastatic to the liver (mCRC) and pancreatic cancer metastatic to the liver.

Liquidity and Operating Matters

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $305.6 million at September 30, 2017. As shown in the accompanying financial statements during the three and nine months ended September 30, 2017, the Company incurred net losses of $12.6 million and $25.9 million, respectively and during the nine months ended September 30, 2017 used $11.7 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016 and effecting a reverse stock split on November 6, 2017 management believes that in its current reduced operating mode its capital resources will be adequate to fund operations through at least January 2018. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.

Basis of Presentation

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2017 and 2016; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K filed for the period ended December 31, 2016.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

Net Loss per Common Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss per Common Share

(10)

Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. Additionally, for the periods ended September 30, 2017, the deemed dividend related to the Series B Preferred Stock (as discussed further in Note 8) is included with net loss to determine both the basic and diluted loss per share.

The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive:


	September 30,
	2017		2016
Stock options		155		118
Unvested restricted shares		289		54
Warrants		953		21,221

Total		1,397		21,394

General (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Accounting Policies [Abstract]

Liquidity and Operating Matters

Liquidity and Operating Matters

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $305.6 million at September 30, 2017. As shown in the accompanying financial statements during the three and nine months ended September 30, 2017, the Company incurred net losses of $12.6 million and $25.9 million, respectively and during the nine months ended September 30, 2017 used $11.7 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

Liquidity

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Cash Equivalents and Concentrations of Credit Risk

Cash Equivalents and Concentrations of Credit Risk

Restricted Cash

Restricted Cash

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Property, Plant and Equipment

Property, Plant and Equipment

Derivative Instrument Liability

Derivative Instrument Liability

Fair Value Measurements

Fair Value Measurements

•

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

•

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

Revenue Recognition

Revenue Recognition

Deferred Revenue

Deferred Revenue

Selling, General and Administrative

Selling, General and Administrative

Research and Development

Research and Development

Stock Based Compensation

Stock Based Compensation

Income Taxes

Income Taxes

Net Loss per Common Share

Net Loss per Common Share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2016 and 2015 are as follows:


(in thousands, except share data)	2016			2015
Net loss – basic and diluted	$	(17,971	)	$	(14,704	)
Net loss per share – basic and diluted		(10.59	)		(14.56	)
Weighted average shares outstanding – basic and diluted		1,696,237			1,010,105

Shares excluded from the computation of diluted EPS:


	2016		2015
Stock options		41,356		47,221
Unvested restricted shares		18,993		35,955
Warrants		7,216,020		1,128,688

Total		7,276,369		1,211,864

All share numbers presented in this footnote reflect a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016.

Segment Information

Segment Information

Foreign Currency and Currency Translation

Foreign Currency and Currency Translation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements.

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Calculation of net loss and number of shares used to compute basic and diluted earnings per share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2016 and 2015 are as follows:


(in thousands, except share data)	2016			2015
Net loss – basic and diluted	$	(17,971	)	$	(14,704	)
Net loss per share – basic and diluted		(10.59	)		(14.56	)
Weighted average shares outstanding – basic and diluted		1,696,237			1,010,105

Net Loss per Common Share (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Earnings Per Share [Abstract]

Anti-dilutive securities excluded from the computation of earnings per share

The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive:


	September 30,
	2017		2016
Stock options		155		118
Unvested restricted shares		289		54
Warrants		953		21,221

Total		1,397		21,394

Shares excluded from the computation of diluted EPS:


	2016		2015
Stock options		41,356		47,221
Unvested restricted shares		18,993		35,955
Warrants		7,216,020		1,128,688

Total		7,276,369		1,211,864

Inventories (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following:


(in thousands)	September 30, 2017		December 31, 2016
Raw materials	$	328	$	346
Work-in-process		660		214
Finished goods		176		100

Total inventories	$	1,164	$	660

Inventories consist of:


	December 31,		December 31,
(in thousands)	2016		2015
Raw materials	$	346	$	360
Work-in-process		214		251
Finished goods		100		146

Total Inventory	$	660	$	757

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


(in thousands)	September 30, 2017		December 31, 2016
Insurance premiums	$	61	$	501
Taxes		53		—
Security Deposit		50		50
Other¹		221		147

Total prepaid expenses and other current assets	$	385	$	698

1	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at September 30, 2017 and December 31, 2016.

Prepaid expenses and other current assets include the following:


	December 31,		December 31,
(in thousands)	2016		2015
Insurance premiums	$	501	$	625
Kits for clinical use		—		162
Other		197		173

Total prepaid expenses and other current assets	$	698	$	960

Property, Plant, and Equipment (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consist of the following:


(in thousands)	September 30, 2017			December 31, 2016
Buildings and land	$	574		$	556
Enterprise hardware and software		1,648			1,532
Leaseholds		1,659			1,504
Equipment		960			940
Furniture		182			354

Property, plant and equipment, gross		5,023			4,886
Accumulated depreciation		(3,770	)		(3,803	)

Property, plant and equipment, net	$	1,253		$	1,083

Property, plant, and equipment consists of:


	December 31,			December 31,
(in thousands)	2016			2015
Buildings and land	$	556		$	556
Enterprise hardware and software		1,532			1,520
Leaseholds		1,504			1,305
Equipment		940			902
Furniture		354			355

Property, plant and equipment, gross		4,886			4,638
Accumulated depreciation		(3,803	)		(3,506	)

Property, plant and equipment, net	$	1,083		$	1,132

Accrued Expenses (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:


(in thousands)	September 30, 2017		December 31, 2016
Clinical trial expenses	$	1,410	$	1,365
Compensation, excluding taxes		1,132		933
Professional fees		448		286
Short-term portion of lease restructuring		221		216
Other¹		544		607

Total accrued expenses	$	3,755	$	3,407

1	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

Current accrued expenses include the following:


	December 31,		December 31,
(in thousands)	2016		2015
Clinical trial expenses	$	1,365	$	692
Compensation, excluding taxes		933		391
Professional fees		286		220
Short-term portion of lease restructuring		216		219
Other		607		721

Total accrued expenses	$	3,407	$	2,243

Restructuring Expenses (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Restructuring and Related Activities [Abstract]

Schedule of restructuring and related costs

The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017:


(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(155	)

Reserve balance at September 30, 2017	$	665

The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2016:


(in thousands)	Lease Liability
Reserve balance at December 31, 2015	$	1,039
Charges		—
Payments/Utilizations		(219	)

Reserve balance at December 31, 2016	$	820

Convertible Notes Payable (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Debt Disclosure Abstract

Summary of Convertible Notes Outstanding

The following table summarizes the convertible notes outstanding at September 30, 2017:


(in thousands)
Convertible notes payable, principal	$	11,437
Debt discounts		(1,701	)

Net convertible note payable	$	9,736

The following table summarizes the convertible notes outstanding at December 31, 2016:


(in thousands)	December 31, 2016
Convertible notes payable, principal	$	34,351
Debt discounts		(21,008	)

Net convertible note payable	$	13,343

Summary of Common Stock Shares Issued under Notes

The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:


	Number of		Number of		Applicable
	Shares of		Shares of		Conversion		Reduction in
	Common Stock		Preferred Stock		Price		Principal
January 12, 2017		11,753		—	$	126.00	$	1,478,318
January 26 - February 1, 2017¹		4,857		—	$	112.00		544,000
February 10, 2017		43,882		—	$	70.00		3,045,817
February 23 - March 2, 2017¹		2,571		—	$	49.00		126,000
March 13, 2017		117,297		—	$	38.50		4,417,830
April 10, 2017		169,061		—	$	21.00		3,621,286
May 9, 2017		109,367		—	$	17.50		1,913,915
June 7 / July 2, 2017 Exchange Agreement²		689,796		4,200	$	6.09		4,200,000
July 7, 2017		114,286		—	$	17.50		2,000,000
August 4, 2017		38,906		—	$	24.50		1,015,848
August 28, 2017 Restructuring Agreement³		117,171		—	$	10.50		1,200,000

Total		1,418,948					$	23,563,014

¹	During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof.

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders Equity Note Abstract

Stock option activity

Stock option activity for 2016 and 2015 is as follows:


	Stock Option Activity under the Plans
								Weighted Average
				Exercise Price per		Weighted Average		Remaining Life
	Stock Options			Share		Exercise Price		(Years)
Outstanding at December 31, 2014		17,577		$	19.84 - $3,921.92	$	378.08		8.83
Granted		32,765			19.04		19.04
Forfeited		(3,121	)		19.04 - 2,713.60		480.16

Outstanding at December 31, 2015		47,221			19.04 - 3,921.92	$	122.40		8.95

Granted		—			—		—
Forfeited		(5,865	)	$	19.04 - $545.28		23.95

Outstanding at December 31, 2016		41,356		$	19.84 - $3,788.80	$	135.77		7.90

Exercisable at December 31, 2016		26,774		$	19.04 - $3,788.80	$	199.31		7.63

Assumptions used to determine estimated fair value of stock options granted

the following assumptions for option grants during the year ended December 31, 2015. There were no option grants during the year ended December 31, 2016:


	Year ended December 31, 2015
Weighted average risk-free interest rates		1.82	%
Weighted average expected volatility		97.70	%
Dividend yield		—
Weighted average expected option term (in years)		5.15
Weighted average grant date fair value	$	0.89

Summary of non-vested options

A summary of the Company’s non-vested options to purchase shares as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below:


	Non-Vested Options
				Weighted
	Number of			Average
	Options			Exercise Price
Non-vested at January 1, 2015		14,116		$	332.16
Granted		32,765			28.48
Vested		(9,994	)		421.60
Forfeited		(1,416	)		574.72

Non-vested at December 31, 2015		35,471		$	22.55
Granted		—			—
Vested		(15,671	)		26.85
Forfeited		(5,218	)		19.23

Non-vested at December 31, 2016		14,582		$	19.11

Summary of restricted stock activity

A summary of the Company’s restricted stock activity as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below:


	Restricted Stock Activity
				Weighted
				Average
	Number			Grant Date
	of Shares			Fair Value
Non-vested at January 1, 2015		1,857		$	269.44
Granted		36,000			41.60
Vested		(1,854	)		217.60
Forfeited		(8	)		54.40

Non-vested at December 31, 2015		35,995		$	19.04
Granted		4,687			4.32
Vested		(19,189	)		15.44
Forfeited		(2,500	)		19.04

Non-vested at December 31, 2016		18,993		$	19.04

Summary of warrant activity

The Company issued warrants as part of its offerings in 2013, 2015, and 2016, as well as part of its issuance of convertible notes in 2016. A summary of warrant activity is as follows:


						Weighted		Weighted
						Average		Average
				Exercise Price		Exercise		Remaining
	Warrants			per Share		Price		Life (Years)
Outstanding at January 1, 2014		53,134			28.00-112.64	$	86.69		2.78
Issued		1,091,844					12.80
Exercised		(13,457	)				13.12
Expired		(2,833	)				13.12

Outstanding at December 31, 2015		1,128,688			11.84-112.64	$	16.02		2.16
Issued		7,031,929					4.80
Exercised		(499,633	)				2.75
Expired		(444,964	)				5.68

Outstanding at December 31, 2016		7,216,020			1.61-112.64	$	5.20		5.59

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Fair Value Measurements (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of fair value of the warrants

The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions:


	October 2016 Warrants			July 2015 Series A Warrants			February 2015 Warrants			October 2013 Warrants
Expected volatility		142.46	%		165.32	%		181.24	%		227.68	%
Risk-free interest rates		1.77	%		1.59	%		1.53	%		1.33	%
Expected life (in years)		4.02			2.81			2.38			1.08

The fair value of the Warrants at December 31, 2016 was determined by using option pricing models assuming the following:


	October			June 2016			July 2015			February			October
	2016			Series C			Series A			2015			2013
	Warrants			Warrants			Warrants			Warrants			Warrants
Expected volatility		95.03	%		94.19	%		95.51	%		95.52	%		152.70	%
Risk free interest rates		1.93	%		2.01	%		1.59	%		1.47	%		1.20	%
Expected life (in years)		4.80			5.50			3.60			3.10			1.80

Assets and liabilities measured at fair value on a recurring basis


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
							Balance at
							September 30,
(in thousands)	Level 1		Level 2		Level 3		2017
Liabilities
Derivative instrument liabilities	$	—	$	—	$	16	$	16

Assets and Liabilities Measured at Fair Value on a Recurring Basis


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
													Balance at
	Level 1				Level 2				Level 3				December 31,
(in thousands)	2016		2015		2016		2015		2016		2015		2016		2015
Liabilities
Derivative instrument liabilities	$	—	$	—	$	—	$	—	$	18,751	$	3,785	$	18,751	$	3,785

Fair value measurements using significant unobservable inputs

The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(1,227	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		—
Fair value of warrants exercised		(19	)

Balance at September 30, 2017	$	16

Fair Value Measurements Using Significant Unobservable

Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at January 1, 2015	$	225
Total change in the liability included in earnings		(564	)
Fair value of warrants issued		4,247
Fair value of warrants exercised		(123	)

Balance at December 31, 2015		3,785
Total change in the liability included in earnings		(12,780	)
Fair value of warrants issued		28,472
Fair value of warrants exercised		(726	)

Balance at December 31, 2016	$	18,751

Commitments (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments, net of receipts due under terms of subleases under all operating leases

Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2016 are as follows:


	Future Lease
(in thousands)	Payment
2017	$	952
2018		946
2019		529
2020		428
2021		254
2022		—

	$	3,109

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Income Before Income Taxes

There is no income tax provision for the years ended December 31, 2016 and 2015. Income before income taxes consists of:


	Year Ended December 31,
(in thousands)	2016			2015
Domestic	$	(13,930	)	$	(11,276	)
Foreign		(4,040	)		(3,428	)

Income before taxes	$	(17,970	)	$	(14,704	)

Income tax reconciliation

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:


	Year Ended December 31,
(in thousands)	2016			2015
Income taxes using U.S federal statutory rate	$	(6,110	)	$	(4,999	)
Loss of tax benefit of net operating loss carryforwards		68,795			—
Loss of tax benefit of state net operating loss carryforwards		13,891			—
Loss of tax benefit of tax credit carryforwards		4,023			—
Amortization of gain on IP migration		767			767
State income taxes, net of federal benefit		(2,576	)		380
Foreign rate differential		1,141			920
Valuation allowance		(75,407	)		2,649
Derivative charge		(4,345	)		(192	)
Stock option exercises and cancellations		53			674
Research and development costs		(250	)		(199	)
Other		18			—

	$	—		$	—

Significant components of deferred tax assets

Significant components of the Company’s deferred tax assets are as follows:


(in thousands)	December 31, 2016		December 31, 2015
Deferred tax assets:
Employee compensation accruals	$	1,386	$	1,279
Accrued liabilities		343		633
Research tax credits		22		3,796
Other		55		66
Net operating losses		6,194		77,906

Total deferred tax assets	$	8,000	$	83,680

Deferred tax liabilities:
Beneficial conversion feature		906		—

Total deferred tax liabilities	$	906	$	—

Valuation allowance		7,094		83,680

Net deferred tax assets	$	—	$	—

Summary of Change in Valuation Allowance

The primary reason for the significant decrease in the valuation allowance during the current year is due to the reduction of recognizable deferred tax assets related net operating loss and credit carryforwards resulting from the Sec. 382 ownership change. The change in valuation allowance is as follows:


(in thousands)	December 31, 2016			December 31, 2015
Beginning balance	$	83,680		$	81,223
Charged to costs and expenses		(75,407	)		2,649
Charged to additional paid-in capital		(1,854	)		—
Charged to retained earnings		1,010			—
Charged to other comprehensive income		(335	)		(192	)

Ending balance	$	7,094		$	83,680

Description of Business - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) Installment	Dec. 31, 2015 USD ($)	Jun. 30, 2016 USD ($)	Jun. 13, 2016 USD ($)
Organization Consolidation and Presentation of Financial Statements [Line Items]
Net loss	$ 12,596,000	$ 1,004,000	$ 25,873,000	$ 9,485,000	$ 17,971,000	$ 14,704,000
Net cash used in operating activities			11,659,000	$ 10,597,000	14,213,000	16,420,000
Accumulated deficit	305,587,000		305,587,000		$ 279,188,000	$ 261,217,000
Senior Secured Convertible Notes [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, original issuance date					Jun. 13, 2016
Debt instrument, principal face amount	$ 11,437,000		$ 11,437,000		$ 34,351,000		$ 35,000,000	$ 35,000,000
Debt instrument payable number of equal installments \| Installment					14

Summary of Significant Accounting Policies - Additional Information (Detail)						1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 02, 2017 USD ($)	Jul. 21, 2016	Jul. 19, 2016	Jun. 13, 2016 USD ($)	Jun. 06, 2016 USD ($)	Dec. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Segment	Sep. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Maximum period of investments with original maturities from date of acquisition to be cash equivalents								3 months
Reverse stock split ratio		0.0625
Number of business segments \| Segment								1
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives								3 years
Reverse stock split ratio			0.1
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives								7 years
Reverse stock split ratio			0.05
Series C Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of notes available for general corporate purposes					$ 2,100,000
Senior Secured Convertible Notes [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, principal face amount				$ 35,000,000		$ 34,351,000		$ 34,351,000	$ 11,437,000	$ 35,000,000
Senior Secured Convertible Notes [Member] \| Series C Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, principal face amount										$ 35,000,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, principal face amount				35,000,000	35,000,000
Cash proceeds from notes held				29,200,000		26,200,000		26,200,000
Proceeds from issuance of notes available for general corporate purposes	$ 3,000,000			3,000,000	3,000,000	3,000,000	$ 6,600,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member] \| Series C Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of notes				32,200,000	$ 32,200,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member] \| First Release Date on December 29, 2016 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash proceeds from notes held				3,000,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member] \| Subsequent Release Dates Beginning in February 2017 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash proceeds from notes held				$ 26,200,000		$ 26,200,000		$ 26,200,000

Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Dec. 31, 2016

Dec. 31, 2015

Calculation of net loss and the number of shares used to compute basic and diluted earnings per share [Abstract]

Net loss - basic and diluted

$ (12,596)

$ (1,004)

$ (25,873)

$ (9,485)

$ (17,971)

$ (14,704)

Net loss per share - basic and diluted

^[1]

$ (9.36)

$ (230.99)

$ (34.99)

$ (2,232.30)

$ (10.59)

$ (14.56)

Weighted average shares outstanding - basic and diluted

^[1]

1,401,413

4,349

754,421

4,249

1,696,237

1,010,105

[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

Summary of Significant Accounting Policies - Summary of Shares Excluded from the Computation of Diluted EPS (Detail) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,397	21,394	7,276,369	1,211,864
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	155	118	41,356	47,221
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	289	54	18,993	35,955
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	953	21,221	7,216,020	1,128,688

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 328	$ 346	$ 360
Work-in-process	660	214	251
Finished goods	176	100	146
Total inventories	$ 1,164	$ 660	$ 757

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 61	$ 501	$ 625
Kits for clinical use			162
Taxes	53
Security Deposit	50	50
Other	221	147	173
Other prepaid expense including security deposit		197
Total prepaid expenses and other current assets	$ 385	$ 698	$ 960

Prepaid Expenses and Other Current Assets - Additional Information (Detail)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%	5.00%

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,023	$ 4,886	$ 4,638
Accumulated depreciation	(3,770)	(3,803)	(3,506)
Property, plant and equipment, net	1,253	1,083	1,132
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	574	556	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,648	1,532	1,520
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,659	1,504	1,305
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	960	940	902
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 182	$ 354	$ 355

Property, Plant, and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 100	$ 100	$ 198	$ 232	$ 305	$ 617

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Clinical trial expenses	$ 1,410	$ 1,365	$ 692
Compensation, excluding taxes	1,132	933	391
Professional fees	448	286	220
Short-term portion of lease restructuring	221	216	219
Other	544	607	721
Total accrued expenses	$ 3,755	$ 3,407	$ 2,243

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Detail)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%	5.00%

Restructuring Expenses - Additional Information (Detail) $ in Thousands			1 Months Ended		9 Months Ended	12 Months Ended
	Aug. 18, 2014 USD ($)	May 22, 2014 USD ($)	Aug. 18, 2014 USD ($)	May 22, 2014 USD ($)	Sep. 30, 2017 USD ($) Lease	Dec. 31, 2016 USD ($) Lease	Dec. 31, 2015 USD ($)
Lease Liability [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases \| Lease					2	2
Restructuring reserve charges					$ 0	$ 0
Restructuring reserve balance					665	820	$ 1,039
Lease Liability [Member] \| Accrued Liabilities [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance					300	200
Lease Liability [Member] \| Other Noncurrent Liabilities [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance					$ 400	$ 600
Sub-lease 1 [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900		$ 900
Sub Lease 2 [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700		$ 700

Restructuring Expenses - Schedule of Restructuring and Related Costs (Detail) - Lease Liability [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 820	$ 1,039
Charges	0	0
Payments/Utilizations	(155)	(219)
Restructuring reserve balance	$ 665	$ 820

Convertible Notes Payable - Additional Information (Detail)																						1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended		19 Months Ended
	Nov. 06, 2017	Oct. 11, 2017 USD ($) $ / shares	Oct. 10, 2017 USD ($) Investor Days $ / shares shares	Sep. 21, 2017 USD ($) $ / shares shares	Sep. 15, 2017 USD ($) $ / shares shares	Aug. 28, 2017 USD ($) $ / shares shares	Aug. 04, 2017 USD ($) $ / shares	Jul. 07, 2017 USD ($) $ / shares	Jul. 02, 2017 USD ($) $ / shares shares	May 09, 2017 USD ($) $ / shares	Apr. 30, 2017 USD ($)	Apr. 10, 2017 USD ($) $ / shares	Apr. 02, 2017 USD ($)	Mar. 13, 2017 USD ($) $ / shares	Mar. 02, 2017 USD ($) $ / shares	Feb. 10, 2017 USD ($) $ / shares	Feb. 01, 2017 USD ($) $ / shares	Jan. 12, 2017 USD ($) $ / shares	Jul. 21, 2016	Jun. 13, 2016 USD ($)	Jun. 06, 2016 USD ($) Installment $ / shares shares	Dec. 31, 2016 USD ($) $ / shares	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($)	Dec. 31, 2017	Jun. 30, 2016 USD ($)
Debt Instrument [Line Items]
Debt instrument, conversion price \| $ / shares							$ 24.50	$ 17.50		$ 17.50		$ 21.00		$ 38.50	$ 49.00	$ 70.00	$ 112.00	$ 126.00
Gain on warrant extinguishment																							$ 0		$ 0	$ 9,613,000	$ 0
Warrant liability fair value adjustment																							(27,000)		$ (8,680,000)	(1,227,000)	(9,171,000)	$ (12,780,000)	$ (564,000)
Conversion of convertible notes						$ 23,563,014	$ 1,015,848	$ 2,000,000		$ 1,913,915		$ 3,621,286		$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318								26,199,000	0	649,000
Reverse stock split ratio																			0.0625
Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																				$ 35,000,000		$ 34,351,000	11,437,000			11,437,000		34,351,000			$ 35,000,000
Debt discount on senior notes																						21,008,000	1,701,000			1,701,000		$ 21,008,000
Debt instrument, original issuance date																												Jun. 13, 2016
Debt issuance costs																						1,000,000						$ 1,000,000
Amortization of debt issuance costs																												$ 300,000
Stock issued to holders as payment on convertible notes payable \| shares																												1,800,000
Conversion of convertible notes																												$ 600,000
Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																				35,000,000	$ 35,000,000
Debt discount on senior notes																					2,800,000	35,000,000	35,000,000			$ 35,000,000		$ 35,000,000
Rate of interest in event of default																										15.00%		15.00%
Proceeds from issuance of notes available for general corporate purposes													$ 3,000,000							3,000,000	$ 3,000,000	3,000,000		$ 6,600,000
Net cash proceeds from notes held in master restricted account as security																				$ 29,200,000		26,200,000						$ 26,200,000
Amortization payments number of equal installments \| Installment																					14
Period after original date of issuance of notes for which amortization payment begins																				7 months
Debt instrument, conversion price \| $ / shares																					$ 1,536.50
Beneficial conversion feature																										$ 4,400,000		4,400,000
Debt discount amortization																										33,300,000		14,000,000
Debt instrument, put options issued on default and change in control, value																						0	0			0		0
Debt issuance costs																							$ 1,800,000			1,800,000
Amortization of debt issuance costs																										$ 1,200,000
Interest rate upon default																							0.00%			0.00%
Debt instrument interest rate computation terms																										The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable
Subsequent Release Dates Beginning in February 2017 [Member] \| Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Net cash proceeds from notes held in master restricted account as security																				$ 26,200,000		26,200,000						26,200,000
Scenario, Previously Reported [Member] \| Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price \| $ / shares																					$ 4.39
Cash [Member] \| Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants																										$ 7,300,000
Net cash proceeds from notes held in master restricted account as security																						$ 26,200,000						$ 26,200,000
Series C Warrants [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes available for general corporate purposes																					$ 2,100,000
Exercise price of warrants \| $ / shares																						$ 4.83						$ 4.83
Aggregate amount to be paid in exchange for cancellation of warrants																										7,876,000	0
Series C Warrants [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																															$ 35,000,000
Series C Warrants [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Additional issuance of common stock purchase price per share \| $ / shares																					$ 0.01
Debt discount on senior notes																					$ 27,800,000
Warrant exercisable period after vesting																					5 years
Warrant exercisable date																					Jun. 13, 2017
Exercise price of warrants \| $ / shares																					$ 4.83
Series C Warrants [Member] \| Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants																				$ 32,200,000	$ 32,200,000
Debt discount on senior notes																					$ 27,800,000
Shares issuable upon warrants exercised \| shares																					20,000
Series C Warrants [Member] \| Scenario, Forecast [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Conditional percentage of increase in number of shares issuable upon exercise of warrants																														75.00%
Series C Warrants [Member] \| Scenario, Previously Reported [Member] \| Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised \| shares																					6,800,000
Subsequent Event [Member]
Debt Instrument [Line Items]
Reverse stock split ratio	0.0029
New Warrants [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised \| shares					2.125
Series A and Series B Preferred Shares [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock																										$ 2,360,000	$ 0
Series A and Series B Preferred Shares [Member] \| Securities Purchase Agreement [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock																							$ 2,400,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Stock issued to holders as payment on convertible notes payable \| shares									4,200
Preferred stock redemption price per share \| $ / shares									$ 0.001
Series A Preferred Stock [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Conversion of convertible notes									$ 4,200,000
Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Stock issued to holders as payment on convertible notes payable \| shares				590
Conversion of convertible notes				$ 500,000
Preferred stock redemption price per share \| $ / shares				$ 1,000.00
Warrant Repurchase Agreements [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants											$ 7,876,000		7,900,000
Gain on warrant extinguishment													9,600,000
Warrant liability fair value adjustment													$ 17,500,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Conversion of convertible notes						1,200,000
Restructuring Agreement [Member] \| Investor [Member]
Debt Instrument [Line Items]
Initial release of restricted cash						1,650,000
Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes						11,444,637
Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member] \| Restricted Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes						10,092,857
Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member] \| Unrestricted Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes						$ 1,351,780
Restructuring Agreement [Member] \| Series A Preferred Stock [Member] \| Investor [Member]
Debt Instrument [Line Items]
Number of preferred stock \| shares						4,200
Preferred stock redemption price per share \| $ / shares						$ 4.20
Restructuring Agreement [Member] \| Series B Convertible Preferred Stock [Member] \| Investor [Member]
Debt Instrument [Line Items]
Number of preferred stock \| shares						2,006
Restructuring Agreement [Member] \| Series B Preferred Stock [Member] \| Investor [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock						$ 2,006,000
Additional Restructuring [Member] \| Investor [Member]
Debt Instrument [Line Items]
Reverse stock split ratio					20
Additional Restructuring [Member] \| Investor [Member] \| Redemption Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount					$ 4,000,000
Debt instrument, redemption price					6,436,852.80
Additional Restructuring [Member] \| Investor [Member] \| Exchange Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount					$ 2,436,852.80
Additional Restructuring [Member] \| Investor [Member] \| New Warrants [Member]
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares					$ 122.50
Warrants expiry period					42 months
Additional Restructuring [Member] \| Investor [Member] \| New Warrants [Member] \| Exchange Notes [Member]
Debt Instrument [Line Items]
Common stock shares purchased \| shares					114,286
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares			$ 122.50
Warrants issued to purchase Common Stock \| shares			127,551
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price \| $ / shares		$ 0.05
Conversion of convertible notes			$ 279,015
Number of Notes investors entered into agreement \| Investor			2
Conversion price of debt instrument to purchase price of common stock percentage.		200.00%
Debt instrument, maturity description			The maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018
Debt instrument maturity date		Dec. 30, 2018	Dec. 30, 2018
Debt instrument, deferred description			Until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period
Debt instrument, conversion threshold days \| Days			75
Debt instrument, redemption description			The Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes
Redemption of outstanding debt instrument for cash		$ 7,300,000	$ 7,300,000
Cash held in the restricted accounts			600,000
Amendment to Restructuring Agreement [Member] \| Series C Preferred Shares [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Redemption of shares outstanding for cash payment			$ 590,000

Convertible Notes Payable - Summary of Convertible Notes Outstanding (Detail) - Senior Secured Convertible Notes [Member] - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Jun. 13, 2016
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 11,437,000	$ 34,351,000	$ 35,000,000	$ 35,000,000
Debt discounts	(1,701,000)	(21,008,000)
Net convertible note payable	$ 9,736,000	$ 13,343,000

Stockholders' Equity - Reverse Stock Split - Additional Information (Detail)	Nov. 06, 2017 $ / shares shares	Jul. 21, 2016 $ / shares shares	Jul. 19, 2016 shares	Sep. 30, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares	Jul. 18, 2016 shares	Dec. 31, 2015 $ / shares shares
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.0625
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01		$ 0.01	$ 0.01		$ 0.01
Common stock, shares authorized (in shares)			500,000,000	500,000,000	500,000,000	170,000,000	500,000,000
Number of fractional shares were issued in connection with the reverse stock split		0
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.05
Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] \| OTCQB [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Number of fractional shares were issued in connection with the reverse stock split	0

Stockholders' Equity - Stock and Warrant Issuances - Additional Information (Detail) - USD ($)	1 Months Ended				3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Mar. 31, 2016	Sep. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Jun. 13, 2016	Dec. 31, 2015	Oct. 20, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Sale of common stock, net of expenses (in shares)	1,215	1,715	440	234
Proceeds from issuance of private placement	$ 1,200,000		$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement	$ 1,100,000		$ 2,500,000	$ 6,900,000
Number of warrants outstanding (in shares)							7,216,020			1,128,688		53,134
Term period for warrants							5 years
Sale of units to underwriter		1,715
Proceeds of common stock issued, net of related expenses		$ 6,000,000
Senior Secured Convertible Notes [Member]
Class Of Warrant Or Right [Line Items]
Debt instrument, principal face amount						$ 11,437,000	$ 34,351,000	$ 35,000,000	$ 35,000,000
Scenario, Previously Reported [Member]
Class Of Warrant Or Right [Line Items]
Sale of common stock, net of expenses (in shares)	425,000	600,000	153,750	81,875
Sale of units to underwriter		600,000
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable per share price (in dollars per share)							$ 112.64			$ 112.64		$ 112.64
Maximum offering and selling of stock and securities that entity make to raise capital											$ 77,400,000
Entity public float pursuant to SEC regulations											$ 75,000,000
Series A Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable per share price (in dollars per share)						$ 49.00	$ 1.61
Number of warrants outstanding (in shares)						500	300,000
Warrants exercised (in shares)							300,000
Net proceeds from exercise of warrants						$ 15,000	$ 400,000
Number of warrants converted		1,140			285	285
Gross proceeds from underwriting offering		$ 7,000,000
Warrants expiry period						5 years
Series A Common Stock Warrants [Member] \| Scenario, Previously Reported [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants converted		400,000
Series B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercised (in shares)					285		100,000
Net proceeds from exercise of warrants					$ 0.8		$ 800,000
Number of warrants converted		1,715
Remaining outstanding warrants expired					1,140		400,000
Warrants expiration date					Jan. 29, 2016		Jan. 29, 2016
Series A And B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Value of warrants issued		$ 3,400,000
2013 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)				106
Value of warrants issued				$ 1,900,000
Warrants exercisable per share price (in dollars per share)						$ 39,424.00	$ 112.64
Number of warrants outstanding (in shares)						100	36,848
Term period for warrants						5 years
2013 Warrants [Member] \| Scenario, Previously Reported [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)				37,000
February 2015 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)			197
Value of warrants issued			$ 800,000
Warrants exercisable per share price (in dollars per share)						$ 49.00	$ 1.61
Number of warrants outstanding (in shares)						100	30,238
Term period for warrants						5 years	5 years
Warrants exercised (in shares)							40,000
Net proceeds from exercise of warrants							$ 100,000
February 2015 Warrants [Member] \| Scenario, Previously Reported [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)			69,000
October 2016 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)	425
Value of warrants issued	$ 300,000
Warrants exercisable per share price (in dollars per share)						$ 49.00	$ 1.61
Number of warrants outstanding (in shares)						200	78,750
Term period for warrants						5 years	5 years
Warrants exercised (in shares)							70,000
Net proceeds from exercise of warrants							$ 100,000
October 2016 Warrants [Member] \| Scenario, Previously Reported [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)	148,750
Series C Warrants [Member]
Class Of Warrant Or Right [Line Items]
Value of warrants issued								$ 27,800,000
Warrants exercisable per share price (in dollars per share)							$ 4.83
Number of warrants outstanding (in shares)							6,800,000
Percentage of increased number of warrant shares issuable upon exercise							75.00%
Description of warrant issued upon exercise							On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events).
Warrants holding period							1 year
Warrants exercisable period							5 years
Series C Warrants [Member] \| Senior Secured Convertible Notes [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants converted								6,800,000
Debt instrument, principal face amount								$ 35,000,000

Stockholders' Equity - Stock Incentive Plans - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation expense				$ 48,000	$ 138,000	$ 161,000	$ 349,000
Additional compensation expense relating to stock options						55,000
Restricted stock compensation expense				84,000	228,000	266,000	$ 308,000
Additional compensation expense relating to restricted stock						$ 100,000
Stock options granted							32,765
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining average recognition period for unrecognized compensation expense						1 year 1 month 13 days
Restricted stock compensation expense		$ 20,000	$ 38,000	$ 100,000	$ 200,000	$ 300,000	$ 300,000
Stock options granted				264	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation expense		$ 3,000.0	$ 24,000.0	$ 48,000.0	$ 100,000	$ 200,000	$ 300,000
Remaining average recognition period for unrecognized compensation expense						1 year 22 days
Aggregate intrinsic value of options outstanding and exercisable						$ 0
Closing stock price (in dollars per share)						$ 0.92
Stock options granted				43	0
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, term				10 years		10 years
2004 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		34		34		11,719
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	269	573		573		200,391
Increased number of shares (in shares)	304
Shares available for grant		55		55		120,883
2009 Stock Incentive Plan [Member] \| Scenario, Previously Reported [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	94,141
Increased number of shares (in shares)	106,250

Stockholders' Equity - Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Options, Number of Options [Roll Forward]
Outstanding, beginning of period (in shares)	47,221	17,577
Granted (in shares)		32,765
Forfeited (in shares)	(5,865)	(3,121)
Outstanding, end of period (in shares)	41,356	47,221	17,577
Exercisable (in shares)	26,774
Stock Options, Exercise Price per Share [Roll Forward]
Granted (in dollars per share)		$ 19.04
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 122.40	378.08
Granted (in dollars per share)		19.04
Forfeited (in dollars per share)	23.95	480.16
Outstanding, beginning of period (in dollars per share)	135.77	$ 122.40	$ 378.08
Exercisable (in dollars per share)	$ 199.31
Stock Options, Weighted Average Remaining Life Years [Abstract]
Outstanding	7 years 10 months 24 days	8 years 11 months 12 days	8 years 9 months 29 days
Exercisable	7 years 7 months 17 days
Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 19.04	$ 19.84
Forfeited (in dollars per share)	19.04	19.04
Outstanding, end of period (in dollars per share)	19.84	19.04	$ 19.84
Exercisable (in dollars per share)	19.04
Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	3,921.92	3,921.92
Forfeited (in dollars per share)	545.28	2,713.60
Outstanding, end of period (in dollars per share)	3,788.80	$ 3,921.92	$ 3,921.92
Exercisable (in dollars per share)	$ 3,788.80

Stockholders' Equity - Assumptions Used to Determine Estimated Fair Value of Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2015 $ / shares
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average grant date fair value (in dollars per share)	$ 28.48
Stock Options [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average risk-free interest rates (in hundredths)	1.82%
Weighted average expected volatility (in hundredths)	97.70%
Weighted average expected option term (in years)	5 years 1 month 24 days
Weighted average grant date fair value (in dollars per share)	$ 0.89

Stockholders' Equity - Summary of Non-vested Options (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Non-vested Options, Number of Options [Roll Forward]
Non-vested, beginning of period (in shares)	35,471	14,116
Granted (in shares)		32,765
Vested (in shares)	(15,671)	(9,994)
Forfeited (in shares)	(5,218)	(1,416)
Non-vested, end of period (in shares)	14,582	35,471
Non-vested Options, Weighted Average Exercise Price [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 22.55	$ 332.16
Granted (in dollars per share)		28.48
Vested (in dollars per share)	26.85	421.60
Forfeited (in dollars per share)	19.23	574.72
Non-vested, end of period (in dollars per share)	$ 19.11	$ 22.55

Stockholders' Equity - Summary of Restricted Stock Activity (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock, Number of Shares [Roll Forward]
Outstanding, beginning of period (in shares)	35,995	1,857
Granted (in shares)	4,687	36,000
Vested (in shares)	(19,189)	(1,854)
Forfeited (in shares)	(2,500)	(8)
Outstanding, end of period (in shares)	18,993	35,995
Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 19.04	$ 269.44
Granted (in dollars per share)	4.32	41.60
Vested (in dollars per share)	15.44	217.60
Forfeited (in dollars per share)	19.04	54.40
Non-vested, end of period (in dollars per share)	$ 19.04	$ 19.04

Stockholders' Equity - Summary of Warrant Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	1,128,688	53,134
Issued (in shares)	7,031,929	1,091,844
Exercised (in shares)	(499,633)	(13,457)
Expired (in shares)	(444,964)	(2,833)
Outstanding, end of period (in shares)	7,216,020	1,128,688	53,134
Warrants, Weighted Average Exercise Price [Roll Forward]
Weighted average remaining life	5 years 7 months 2 days	2 years 1 month 28 days	2 years 9 months 11 days
Outstanding, beginning of period (in dollars per share)	$ 16.02	$ 86.69
Issued (in dollars per share)	4.80	12.80
Exercised (in dollars per share)	2.75	13.12
Expired (in dollars per share)	5.68	13.12
Outstanding, end of period (in dollars per share)	5.20	16.02	$ 86.69
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	1.61	11.84	28
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 112.64	$ 112.64	$ 112.64

Stockholders' Equity - Summary of Warrant Activity (Parenthetical) (Detail) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Minimum [Member]
Outstanding, (in dollars per share)	$ 1.61	$ 11.84	$ 28

Fair Value Measurements - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Input	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) Input	Dec. 31, 2015 USD ($)
Fair Value Disclosures [Abstract]
Number of inputs used for valuation of warrants \| Input			6		6
Derivative warrant liability [Abstract]
Change in fair value of the warrant liability, net	$ (27)	$ (8,680)	$ (1,227)	$ (9,171)	$ (12,780)	$ (564)
Derivative warrant liabilities	$ 16		$ 16		$ 18,751	$ 3,785

Fair Value Measurements - Schedule of Fair Value of Warrants (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
October 2016 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	142.46%	95.03%
Risk-free interest rates (in hundredths)	1.77%	1.93%
Expected life (in years)	4 years 7 days	4 years 9 months 18 days
June 2016 Series C Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)		94.19%
Risk-free interest rates (in hundredths)		2.01%
Expected life (in years)		5 years 6 months
July 2015 Series A Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	165.32%	95.51%
Risk-free interest rates (in hundredths)	1.59%	1.59%
Expected life (in years)	2 years 9 months 22 days	3 years 7 months 6 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	181.24%	95.52%
Risk-free interest rates (in hundredths)	1.53%	1.47%
Expected life (in years)	2 years 4 months 17 days	3 years 1 month 6 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	227.68%	152.70%
Risk-free interest rates (in hundredths)	1.33%	1.20%
Expected life (in years)	1 year 29 days	1 year 9 months 18 days

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Derivative Instruments Liabilities [Member] - Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Liabilities [Abstract]
Total Liabilities	$ 16	$ 18,751	$ 3,785
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 16	$ 18,751	$ 3,785

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 18,751	$ 3,785	$ 3,785	$ 225
Total change in the liability included in earnings	(1,227)		(12,780)	(564)
Extinguishment of convertible note warrant	(17,489)
Fair value of warrants issued	0	28,133	28,472	4,247
Fair value of warrants exercised	(19)	$ (245)	(726)	(123)
Ending balance	$ 16		$ 18,751	$ 3,785

Commitments Additional Information (Detail)	1 Months Ended		12 Months Ended
Commitments Additional Information (Detail)	Oct. 31, 2016 USD ($) ft²	Mar. 31, 2016 USD ($) ft²	Dec. 31, 2016 USD ($) ft²	Dec. 31, 2016 EUR (€)	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
Rent expense			$ 500,000		$ 400,000
Office Space at 810 Seventh Avenue, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²			8,629
Expansion option, additional square footage of office space (in square feet) \| ft²			8,629
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement			$ 881,297
Expiration date of letter of credit			Feb. 01, 2017	Feb. 01, 2017
Office Space in New York, NY, Lease Amendment [Member]
Operating Leased Assets [Line Items]
Additional square footage of office space leased under exercise of option right (in square feet) \| ft²			8,629
Lease expiration date			Mar. 31, 2021	Mar. 31, 2021
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] \| Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 996,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] \| Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent			1,000,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] \| Years Thereafter [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 1,100,000
Delcath's European Headquarters Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²			19,200
Operating lease term			10 years	10 years
Delcath's European Headquarters Lease Agreement [Member] \| Year 1 [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 115,458	€ 106,051
Delcath's European Headquarters Lease Agreement [Member] \| Year 2 [Member]
Operating Leased Assets [Line Items]
Annual base rent			146,946	134,974
Delcath's European Headquarters Lease Agreement [Member] \| Year 3 [Member]
Operating Leased Assets [Line Items]
Annual base rent			173,187	159,077
Delcath's European Headquarters Lease Agreement [Member] \| Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent			199,427	183,179
Delcath's European Headquarters Lease Agreement [Member] \| Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent			199,427	183,179
Delcath's European Headquarters Lease Agreement [Member] \| Year 6 Through 10 [Member]
Operating Leased Assets [Line Items]
Annual base rent			197,377	€ 187,209
Office Space At 1633 Broadway, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²		6,877
Annual base rent		$ 522,652
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement			$ 130,663
Expiration date of letter of credit			Mar. 01, 2019	Mar. 01, 2019
Park Road Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) \| ft²	6,000
Annual base rent	$ 48,223
Operating lease term			2 years	2 years
Lease expiration period			2018-10	2018-10

Commitments - Schedule Future Minimum Lease Payments, Net of Receipts Due Under Terms of Subleases Under All Operating Leases (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Future minimum lease payments under all operating leases [Abstract]
2017	$ 952
2018	946
2019	529
2020	428
2021	254
Total future minimum payments due	$ 3,109

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Income tax provision	$ 0	$ 0
Tax benefit related to the exercise of non qualified stock options	$ 1,000,000
Percentage of valuation allowance against deferred tax assets	100.00%
Valuation allowance increase (decrease)	$ (76,600,000)	2,600,000
Unrecognized tax benefits, interest or penalties accrued	$ 0
Tax Year 2013 [Member]
Operating Loss Carryforwards [Line Items]
Open tax period	Dec. 31, 2013
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax period	Dec. 31, 2016
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 21,100,000	22,100,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	209,300,000	184,500,000
Operating loss carryforwards, amount subject to limitations	201,000,000
Operating loss carryforwards, annual limitation	72,500
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income	205,700,000
Federal [Member] \| Research and Development Tax Credit Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 4,000,000	3,800,000
Tax credit carryforwards, expiration dates	2036
Federal [Member] \| Expire Between 2018 and 2036 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 3,600,000
State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 2,800,000	2,700,000
Operating loss carryforwards, expiration dates	2036
Minimum [Member] \| State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 27,300,000	27,300,000
Maximum [Member] \| State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	153,000,000	$ 109,700,000
New York State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income	150,200,000
New York City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income	130,500,000
ASU 2016-09 [Member]
Operating Loss Carryforwards [Line Items]
Income tax benefit cumulative adjustment to retained earnings	1,000,000
Valuation allowance offset against retained earnings	$ 1,000,000

Income Taxes - Schedule of Income Before Income Taxes ( (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments [Abstract]
Domestic	$ (13,930)	$ (11,276)
Foreign	(4,040)	(3,428)
Income before taxes	$ (17,970)	$ (14,704)

Income Taxes - Income tax reconciliation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Provision for income taxes [Abstract]
Income taxes using U.S federal statutory rate	$ (6,110)	$ (4,999)
Loss of tax benefit of net operating loss carryforwards	68,795
Loss of tax benefit of state net operating loss carryforwards	13,891
Loss of tax benefit of tax credit carryforwards	4,023
Amortization of gain on IP migration	767	767
State income taxes, net of federal benefit	(2,576)	380
Foreign rate differential	1,141	920
Valuation allowance	(75,407)	2,649
Derivative charge	(4,345)	(192)
Stock option exercises and cancellations	53	674
Research and development costs	(250)	(199)
Other	18
Total	$ 0	$ 0

Income Taxes - Significant Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Employee compensation accruals	$ 1,386	$ 1,279
Accrued liabilities	343	633
Research tax credits	22	3,796
Other	55	66
Net operating losses	6,194	77,906
Total deferred tax assets	8,000	83,680
Deferred tax liabilities:
Beneficial conversion feature	906
Total deferred tax liabilities	906
Valuation allowance	7,094	83,680	$ 81,223
Net deferred tax assets	$ 0	$ 0

Income Taxes - Summary of Change in Valuation Allowance (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning balance	$ 83,680	$ 81,223
Charged to costs and expenses	(75,407)	2,649
Charged to additional paid-in capital	(1,854)
Charged to retained earnings	1,010
Charged to other comprehensive income	(335)	(192)
Ending balance	$ 7,094	$ 83,680

Subsequent Events - Additional Information (Detail)																	3 Months Ended	9 Months Ended		12 Months Ended
Subsequent Events - Additional Information (Detail)	Nov. 06, 2017 USD ($) $ / shares shares	Oct. 11, 2017 USD ($) Conversion $ / shares	Oct. 10, 2017 USD ($) Investor d $ / shares shares	Sep. 21, 2017 USD ($) shares	Aug. 28, 2017 USD ($)	Aug. 04, 2017 USD ($) $ / shares	Jul. 07, 2017 USD ($) $ / shares	May 09, 2017 USD ($) $ / shares	Apr. 10, 2017 USD ($) $ / shares	Mar. 13, 2017 USD ($) $ / shares	Mar. 02, 2017 USD ($) $ / shares	Feb. 13, 2017 $ / shares	Feb. 10, 2017 USD ($) $ / shares	Feb. 01, 2017 USD ($) $ / shares	Jan. 12, 2017 USD ($) $ / shares	Jul. 21, 2016 $ / shares shares	Mar. 28, 2017 USD ($) shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 $ / shares
Subsequent Event [Line Items]
Closing bid price per NASDAQ listing notification letter \| $ / shares												$ 1.00
Stock market granted additional calendar days												180 days
Stock market granted consecutive trading days preceding the date of notice												30 days
Consecutive business days for closing bid price of common stock												10 days
Conversion of convertible notes					$ 23,563,014	$ 1,015,848	$ 2,000,000	$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000		$ 3,045,817	$ 544,000	$ 1,478,318			$ 26,199,000	$ 0	$ 649,000
Debt instrument, conversion price \| $ / shares						$ 24.50	$ 17.50	$ 17.50	$ 21.00	$ 38.50	$ 49.00		$ 70.00	$ 112.00	$ 126.00
Reverse stock split ratio																0.0625
Number of fractional shares were issued in connection with the reverse stock split \| shares																0
Common stock, par value (in dollars per share) \| $ / shares																$ 0.01		$ 0.01		$ 0.01	$ 0.01
Senior Secured Convertible Notes [Member]
Subsequent Event [Line Items]
Stock issued to holders as payment on convertible notes payable \| shares																				1,800,000
Series C Preferred Shares [Member]
Subsequent Event [Line Items]
Stock issued to holders as payment on convertible notes payable \| shares				590
Conversion of convertible notes				$ 500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] \| OTCQB [Member]
Subsequent Event [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split \| shares	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Subsequent Event [Member] \| Series C Preferred Shares [Member]
Subsequent Event [Line Items]
Preferred shares outstanding for a cash payment	$ 590,000
Master Control Account Agreement [Member]
Subsequent Event [Line Items]
Cash previously funded from holders of notes																	$ 6,600,000
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price of warrants \| $ / shares			$ 122.50
Warrants exercise price description			On the 136th day subsequent to the date of consummation of the offering hereunder, there shall be a "true up" with regard to the issuance of shares upon exercise such that the difference between 382,650 shares and the number of shares that would be issuable if the exercise price were lowered to the average price per share of the variable weighted average price of our common stock for the five trading days commencing on the date which is 76 days after the date of consummation of the offering hereunder, but not lower than 33% of the variable weighted average price of a share of our common stock on the 81st date following the date of consummation of the offering hereunder.
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| On Or After 75th Day Subsequent To Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Shares issuable upon warrants exercised \| shares			382,650
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| After 76 Days from Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Number of trading days required to measure weighted average price of common stock \| d			5
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| On 81st Date Following from Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Minimum percentage of variable weighted average price of share of common stock			33.00%
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| On Or Before 135th Date Following From Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Warrants provision may buy out			$ 6,138,349.80
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| Senior Secured Convertible Notes [Member]
Subsequent Event [Line Items]
Number of Notes investors entered into agreement \| Investor			2
Conversion of convertible notes			$ 279,015
Registration statement on Form S-1 filed date			Oct. 11, 2017
Conversion price of debt instrument to purchase price of common stock percentage.		200.00%
Debt instrument maturity date		Dec. 30, 2018	Dec. 30, 2018
Conversions during 75 day period from date of consummation \| Conversion		0
Redemption of outstanding debt instrument for cash		$ 7,300,000	$ 7,300,000
Debt instrument, conversion price \| $ / shares		$ 0.05
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| Series C Preferred Shares [Member]
Subsequent Event [Line Items]
Preferred shares outstanding for a cash payment			$ 590,000
Common Stock Issued [Member]
Subsequent Event [Line Items]
Stock issued to holders as payment on convertible notes payable \| shares																	109,345,554
Common Stock Issued [Member] \| Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issuable upon warrants exercised \| shares			127,550

General - Additional Information (Detail)			3 Months Ended		9 Months Ended		12 Months Ended
General - Additional Information (Detail)	Nov. 06, 2017 $ / shares shares	Jul. 21, 2016 $ / shares shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($) $ / shares	Jun. 30, 2016 USD ($)	Jun. 13, 2016 USD ($)
Class Of Stock [Line Items]
Reverse stock split ratio		0.0625
Number of fractional shares were issued in connection with the reverse stock split \| shares		0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01	$ 0.01		$ 0.01		$ 0.01	$ 0.01
Net loss			$ 12,596,000	$ 1,004,000	$ 25,873,000	$ 9,485,000	$ 17,971,000	$ 14,704,000
Net cash used in operating activities					11,659,000	$ 10,597,000	14,213,000	16,420,000
Accumulated deficit			305,587,000		305,587,000		279,188,000	$ 261,217,000
Senior Secured Convertible Notes [Member]
Class Of Stock [Line Items]
Debt instrument, principal face amount			$ 11,437,000		$ 11,437,000		$ 34,351,000		$ 35,000,000	$ 35,000,000
Subsequent Event [Member]
Class Of Stock [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] \| OTCQB [Member]
Class Of Stock [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split \| shares	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01

Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Detail) - USD ($)												9 Months Ended		12 Months Ended
	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Applicable Conversion Price		$ 24.50	$ 17.50		$ 17.50	$ 21.00	$ 38.50	$ 49.00	$ 70.00	$ 112.00	$ 126.00
Reduction in Principal	$ 23,563,014	$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318	$ 26,199,000	$ 0	$ 649,000
Exchange Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price				$ 6.09
Reduction in Principal				$ 4,200,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price	$ 10.50
Reduction in Principal	$ 1,200,000
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of Shares	1,418,948	38,906	114,286		109,367	169,061	117,297	2,571	43,882	4,857	11,753
Common Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				689,796
Common Stock Issued [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	117,171
Preferred Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				4,200

Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Parenthetical) (Detail) - USD ($)												3 Months Ended	9 Months Ended		12 Months Ended
	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Reduction in Principal	$ 23,563,014	$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318		$ 26,199,000	$ 0	$ 649,000
Loss on debt settlement												$ 2,952,000	$ 2,952,000	$ 0
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	1,200,000
Loss on debt settlement	$ 2,000,000
Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal				$ 4,200,000
Loss on debt settlement				$ 1,000,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued				4,200
Series A Preferred Stock [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued				4,200
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued	1,418,948	38,906	114,286		109,367	169,061	117,297	2,571	43,882	4,857	11,753
Common Stock Issued [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued	117,171
Common Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued				689,796

Stockholders' Equity - Recent Preferred Stock Issuances - Additional Information (Detail)														1 Months Ended			3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 21, 2017 USD ($) Investor $ / shares Vote shares	Aug. 28, 2017 USD ($) shares	Aug. 04, 2017 USD ($)	Jul. 11, 2017 USD ($) $ / shares Vote	Jul. 07, 2017 USD ($)	Jul. 02, 2017 USD ($) $ / shares Vote shares	May 09, 2017 USD ($)	Apr. 10, 2017 USD ($)	Mar. 13, 2017 USD ($)	Mar. 02, 2017 USD ($)	Feb. 10, 2017 USD ($)	Feb. 01, 2017 USD ($)	Jan. 12, 2017 USD ($)	Oct. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Oct. 31, 2013 USD ($)	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares	Nov. 06, 2017 USD ($)	Sep. 12, 2017 $ / shares	Jun. 29, 2017 $ / shares
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																	$ 0.01	$ 0.01		$ 0.01	$ 0.01
Conversion of convertible notes		$ 23,563,014	$ 1,015,848		$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318					$ 26,199,000	$ 0	$ 649,000
Sale of stock in private placement																				$ 1,011,000	$ 8,479,000
Gross proceeds from the sale of shares														$ 1,200,000	$ 2,600,000	$ 7,500,000
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																								$ 0.01
Number of Shares \| shares						4,200
Closing bid price \| $ / shares						$ 1,288.00
Number of votes \| Vote						3,261
Preferred stock redemption price per share \| $ / shares						$ 0.001
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																								$ 0.01
Closing bid price \| $ / shares				$ 65.35
Number of votes \| Vote				30,607
Sale of stock in private placement				$ 2,360,000
Cash purchase price in private placement				2,000,000
Gross proceeds from the sale of shares				$ 2,000,000
Conversion price per share \| $ / shares				$ 53.55
Deemed dividend amount																	$ 360,000
Series C Preferred Shares [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																							$ 0.01
Conversion of convertible notes	$ 500,000
Number of Shares \| shares	590
Number of votes \| Vote	1,484,061
Preferred stock redemption price per share \| $ / shares	$ 1,000.00
Number of investors \| Investor	2
Subsequent Event [Member] \| Series C Preferred Shares [Member]
Stockholders Equity Note [Line Items]
Redemption of preferred stock																						$ 590,000
Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes		$ 1,200,000
Restructuring Agreement [Member] \| Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Redeemed share \| shares		2,360,000
Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Number of Shares \| shares																				1,800,000
Senior Secured Convertible Notes [Member] \| Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes						$ 4,200,000

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,397	21,394	7,276,369	1,211,864
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	155	118	41,356	47,221
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	289	54	18,993	35,955
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	953	21,221	7,216,020	1,128,688